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Cell-surface carbohydrates—or glycans—influence growth, differentiation, and immune 
response mechanisms. Alterations to the glycome can be markers for diseases including diabetes, 
neurodegenerative disorders, and cancer. Fucosyltransferases catalyze the addition of a fucose 
sugar residue to specific cell-surface glycans, which are involved in intercellular cell 
rolling/adhesion interactions such as white blood cells homing to inflammation sites and sperm-
egg binding in fertilization. Fucosylated glycans are also implicated in inflammatory disease and 
cancers. In viral and microbial infections, fucosyltransferases can play a role in the adhesion and 
colonization of the host organism, as in the case of Helicobacter pylori α(1,3)-fucosyltransferase 
(FucT). 
To better our understanding of glycome alterations and improve medical diagnostics and 
treatments, screens for glycosyltransferase activity and inhibition are needed. Efficient screens for 
specific glycosylations tend toward costly materials, instrumentation, and specialized skillsets- 
here, we present a novel inhibition assay for FucT using the fluorogenically labeled disaccharide, 
MU-β-LacNAc. The assay shows good potential for high throughput (Z’=0.78 in 384-well plate), 
though such an application is not shown here. It was also implemented on a digital microfluidic 
(DMF) platform, where inhibition curves of FucT by GDP, a product of the glycosyltransferase 
reaction that exhibits an inhibitory feed-back loop, were generated on-device. Results of the assay 
on DMF (IC50 = 0.093 mM ± 0.037) were shown to be comparable to results in a 384-well plate 
(IC50 = 0.114 mM ± 0.086), achieving a 87.5% reduction in reaction volume and setting the 
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Chapter 1. Introduction 
 
1.1. Introduction to Cell-surface Glycosylation 
 
1.1.1. General introduction to glycobiology 
 
Glycobiology is the study of the glycosylation of biological components, a process 
by which sugar residues are bound to other molecules. The catalysis of this sugar addition 
to specific target acceptors by enzymes called glycosyltransferases is found ubiquitously in 
all domains of life.1-3 Due to a database study in which the Swiss-Prot protein database was 
scanned for known glycosylation site consensus sequences, it was long held that half of all 
proteins were glycosylated, thus falling under the umbrella term ‘glycoprotein’.4 However, 
a more modest (but still relatively large) proportion was estimated from a more recent 
database study, which employed an algorithm taking into account the body of knowledge 
which had since grown over 12 years to encompass multiple weighted evidence sources for 
glycosylations and their relative abundances, suggesting that it is only a fifth of proteins 
that are glycosylated.5  
As the main component of the extracellular matrix, the dense coat of glycans found 
at the surface of cells is their first contact with the world outside of them, yet glycans have 
sometimes been overlooked in studies.6, 7 With the help of large-scale glycomics initiatives 
like the Collaborative Glycomics Initiative in Europe, the Consortium for Functional 
Glycomics in the U.S.A., and the Human Disease Glycomics/Proteomics Initiative in Japan, 
a mere 52 known glycosyltransferase families with 13 solved crystal structures in 2001 has 
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grown to 106 families with 140 solved crystal structures in 2016.8 This showed a rapid 
increase in efforts to elucidate the mechanisms of their often complex and functionally 
diverse reactions.   
The fields of glycobiology and glycomics have hence gained considerable traction 
in the past few decades, now at the forefront of many forms of research from the more 
efficient utilization of many types of carbohydrate-based biomass (ex.: waste made of 
paper, wood, etc.) as molecular sources to convert into biofuels, to glycan-based clinical 
diagnostics and therapeutics, the latter of which will be the focus of this introduction. 
3 
 
1.1.2. Definition of glycans 
 
Figure 1) Glycosylated protein with molecular depiction of a glycosidic bond. 
Representation of a glycan/oligosaccharide chain tethered to a protein using four of the 
standard color-coded symbols for sugar subunits: Glucose, Galactose, Mannose, and 
Sialic Acid. An α-(1,4) glycosidic bond is depicted between two glucose molecules as 
an example. Molecular structures drawn in ChemDraw. 
 
In mice, every study in which an entire major class of glycans associated to 
vertebrate cells was genetically knocked out has resulted in embryonic lethality.9 To 
understand why glycans are so crucial, we must first examine what they are. The term 
‘glycan’ refers to a broad range of carbohydrate sugars of varying length. They range from 
‘polysaccharides’, which are chains of monosaccharides bound by glycosidic linkages, and 
‘oligosaccharides’ when less than twenty monosaccharides are included, as well as simple 
sugars which comprise a single monosaccharide unit. Glycan chains are extremely diverse 
in composition, length and branching structure. The sugars that compose them are widely 
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represented across the literature by standard color-coded symbols. (Figure 1) The 
glycosidic bonds between them are described by their anomeric properties (α – when the 
O-glycosidic bond from C1 on the first sugar points in the opposite plane from the CH2OH 
on that same sugar (can be referred to as C6), β – when the O-glycosidic bond from C1 on 
the first sugar aligns to the same plane as C6 on that sugar) and the position of the carbon 
on each sugar ring involved in the linkage.  
1.1.3. The role of cell-surface glycosylation 
 
In cells and on their surfaces, glycans mostly occur as post-translational additions 
made to proteins. Two categories of these glycans are the most commonly described, N-
glycans and O-glycans. These are distinguished by the amino acids to which they are 
tethered; the majority are N-glycans, which are attached to an asparagine (Asn) side-chain, 
and a small minority are O-glycans, which are attached to either a serine (Ser) or threonine 
(Thr) side-chain and whose structures tend toward less branching.10, 11  They often 
participate in the fine-tuning of interactions between proteins, as evidenced by the many 
studies in which interference with glycans only subtly alters processes.12 They have many 
other roles in addition to these, sometimes of crucial importance. These can be structural, 
such as in anchoring other proteins to the cell membrane, and even alter chemical properties 
of proteins such as stability in acid and heat as in the case of glycan changes resulting from 
alpha-L-fucosidase activity in the human liver, involved in child autoimmune disorders.13-
15 Most significantly, they have a wide range of regulatory functions through signaling 
mechanisms which control cell-cell recognition, interaction, growth, differentiation, and 
immune response.12, 16 Other categories of glycans exist at the cell surface besides N- and 
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O-glycans, each of them also involved in a diverse range of functions; glycosaminoglycans 
are linear repetitions of a disaccharide, highly abundant in the animal extracellular matrix 
and an important structural component of collagen, for which it acts as a physical spacer 
to order stroma (connective tissues).17 Glycosaminoglycans are also involved in tissue 
repair, with hyaluronan as example; following tissue injury, it is rapidly produced and 
excreted by cells.18 There is also considerable study of glycosylated lipids, referred to as 
glycolipidomics; phosphatidylinositol-linked glycans are involved in the proper formation 
of membranes and vesicles, among other functions, while glycosphingolipids are involved 
in cell-cell signaling, adhesion, and differentiation.19, 20  
Most of the glycans at the cell surface are N-glycans, the most common eukaryotic 
covalent protein modification.21 The mammalian biosynthetic pathway to N-glycan 
formation begins with the assembly of a core oligosaccharide by transmembrane enzymes 
of the endoplasmic reticulum (ER).21, 22  While a new protein is undergoing translation, a 
glycosyltransferase recognizing the consensus N-glycosylation sequence (Asn-X-Ser/Thr)  
catalyzes the formation of an N-glycosidic bond between its specific oligosaccharide and 
the nitrogen side-chain of the asparagine on the protein.23 Beyond this step, most other 
glycosyltransferases exist as type II membrane proteins at the Golgi apparatus, providing 
additional glycosylations to modify and make additions to the core oligosaccharide.24, 25 
Besides the enzymes involved in their construction, glycans interact specifically 
with a great number of proteins both in their immediate environment and on the surfaces 
of other cells, called lectins. These are a unique structural and functional class of proteins 
that recognize oligosaccharide chains; for instance, lacto-N-fucopentaose III is a cell-
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surface glycan which, when recognized by cellular adhesion related proteins, stimulates B 
cell proliferation.26, 27  
To date, there are few, if any, cellular processes left with which glycans have not 
been implicated. Given biological systems simultaneously capable of expressing 
glycosyltransferases which can glycosylate specific target glycans, and glycoside 
hydrolases which can specifically cleave the glycosidic bonds of target oligosaccharides, 
glycans encode another important layer of post-translational programmability in living 
organisms. Hence, their further study could help in decoding biological function and 
eventually result in novel synthetic biological applications. 
 
1.1.4. Abnormal glycosylation as a disease marker 
 
One of the main reasons glycobiology is studied is due to its medical importance, 
given that changes to glycan structure and abundance comprise many markers for 
disease. 28-30 For example, glycans play a role in Alzheimers, Parkinsons, and other 
neurodegenerative diseases; amyloid β protein (Aβ) and the microtubule-associated 
protein Tau are two of the main components of the plaques and tangles they are 
associated with. The abnormal glycosylation of Aβ and Tau in Alzheimers-afflicted 
brains contributes to their pathological filament structuring and aggregation.31-34  
Among the shifts in glycosylation states linked to cancers, changes in 
fucosylation, sialylation, and the branching of glycans are some of the most important.35 
The tumor glycome is characterized by shortened O-glycans, increased sialylation, the 
presence of Lewis-type antigens on glycoproteins and glycolipids, an accumulation of 
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precursor glycans, and the skewed production of glycosylated products, among which the 
notable overproduction of immunosuppressive glycosphingolipids.36-38  
Harnessing the specificity of lectins for their glycan ligands, lectin-based 
glycoproteomic analyses have been developed not only for further glycome studies, but 
also to help in diagnosing patients.39  
 
1.1.5. Medical treatment using glycan-based approaches 
 
Like the distinct morphologies allowing us to identify other species by visual 
observation, immune systems identify foreign cells by ways of the distinct structural 
epitopes of their glycans, which bind to immune-system triggering lectins.40 As an 
evolutionary result, it is common for parasitic organisms and bacteria to express glycans at 
their cell surfaces which mimic those of their host so as to evade immune response.1, 41-43 
In turn, the immunosuppressive effect of glycans from certain parasitic worms such as 
Trichuris suis and Schistosoma japonicum has led to clinical trials which utilized their eggs 
or soluble egg extracts to treat autoimmune diseases such as IBD (Crohn’s Disease).44, 45  
Harnessing glycans to opposite (immunostimulatory) effect, many vaccines have 
and continue to be developed through the covalent conjugation and coupling of glycans to 
an immunogenic carrier protein.46 The glycans of bacteria, protozoans, parasitic worms, 
fungi, viruses as well as cancer cells can then be presented to the immune system for or 
targeting. STn-αGalCer is one such cancer vaccine candidate, made by attaching the tumor-
associated disaccharide sialyl Tn to α-galactosylceramide, a natural killer T cell ligand. It 
has been shown to efficiently switch IgM antibody to STn-specific IgG, demonstrating its 
potential in training the immune system to attack tumor cells.47 Animal vaccinations against 
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Alzheimer’s disease-specific Aβ antigens have also been tested, but the stimulation of 
damaging neuroinflammatory response remains a problem.48 Recent improvements in 
glycan synthesis and yield have contributed to the advancement of this research, which is 
progressing by leaps and bounds, with multiple bacterial vaccines already released on the 
market by Merck & Co., Sanofi Pasteur, and Wyeth Pharmaceuticals, with many more in 
development across many disease categories.46  
The recognition of cell-surface glycans by the immune system is also the same 
principle by which different blood group antigens from one’s own– themselves glycans– 
can trigger an immune response if one is given blood from donors of different blood types.49 
As such, some are pursuing methods of converting other blood groups to universal blood 
groups through glycan-modifying biochemistry.50  
Last but not least, rather than acting as a treatment, pathways that assemble cell-
surface glycans that play a role in disease such as sialyl-LewisX (sLeX) are the targets for 
treatment. In sLeX-deficient patients, insufficient sLeX led to a decrease in leukocyte 
extravasation and hence, insufficient immune response to combat infection.51, 52 Dietary 
supplements of L-fucose are able to restore proper sLeX expression.53 When it comes to 
the inhibition of glycan formation, an increased understanding of the workings of 
glycosylation in disease models has brought the search for inhibitors for glycan-modifying 
proteins to new heights; many such inhibitors in the imino-sugar family are in the 
preclinical or approved stages for a multitude of diseases, from targeting ER α-glucosidases 
to treat Hepatitis B, to inhibiting CerGlcT glycosyltransferases for the treatment of 
lysosomal storage disorders such as Gaucher disease.54-56      
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1.1.6. Focus: the role of cell-surface fucosylation 
 
Figure 2) Fucosylation of Sialyl LacNAc to form Sialyl-LewisX 
A fucosyltransferase catalyzing the addition of a Fucose sugar residue from a GDP-Fucose 
donor to a Sialyl LacNAc receptor glycan, resulting in Sialyl-LewisX, an important cell-
surface glycan. 
 
Fucosyltransferases are one of the glycosyltransferase families that are being pursued as a 
target for drug discovery research. Fucosyltransferases catalyze the transfer of a fucose sugar 
residue from GDP-Fucose to a glycan (Figure 2). In humans, there are 11 fucosyltransferases in 
total, whose usual expression is restricted to certain cell and tissue types. For example, FUT3 is 
highly expressed in the kidney and colon, but not the liver – meanwhile, FUT8 is expressed in the 
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liver, where it contributes to liver tissue regeneration in mice, and FUT9 is the primary α(1,3)-
fucosyltransferase activity in the brain.57-59 Specifically for α(1,3)-fucosyltransferases 
(encompassing FUT3, FUT4, FUT5, FUT6, FUT7, FUT9, FUT10 and FUT11), upregulation can 
result in the increased formation of sialyl-LewisX (sLeX) glycans. These glycans bind to all three 
members of the selectin family of cell adhesion receptors implicated in lymphocyte homing and 
neutrophil extravasation during the course of an immune response, as well as platelet binding in 
the process of wound healing.60, 61 As important modulators of the cell-surface glycome, the under- 
or over-expression of fucosyltransferases sometimes lies at the root of disease. 
1.1.7. Abnormal fucosylation and disease 
 
In the case of the fucosylated cell-surface glycan sLeX, its aberrant heightened expression 
on cell surfaces promotes interaction with selectins, facilitating endothelial crossing and 
adhesion.61, 62 This heightened expression of sLeX and the α(1,3)-fucosyltransferases that 
assemble it has been shown to promote higher metastatic potential, drug resistance, and 




Table 1) Roles played by different human fucosyltransferases in cancer 





Fut 1 With some colorectal cancer cell lines, heightened expression promotes drug 
resistance67 and proliferation.68 With some pancreatic, hepatic and colonic cancer cell 
lines, heightened expression results in a decrease in metastatic potential.69, 70 With an 
ovarian cancer cell line, heightened expression promotes proliferation and drug 
resistance.71 In chronic myeloid leukemia cells, heightened expression promoted 
multidrug resistance72 
Fut 2 With some colon cancer cell lines, lowered expression promoted, or was linked to 






Fut 3 Heightened expression was observed in head, neck, metastatic colon cancer cells, and 
the inhibition of expression decreased proliferation.66, 73, 74  
Fut 4 Heightened expression in hepatocarcinoma cell lines was linked to multidrug 
resistance.64 In an epidermoid carcinoma cell line, overexpression was found to increase 
proliferation.75 
Fut 5 Heightened expression in breast cancer cell lines has been observed.65    
Fut 6 Heightened expression in hepatocarcinoma cell lines was linked to multidrug 
resistance.64  Heightened expression in breast and prostate cancer cell lines has been 
observed and promotes metastasis.65, 76 In colon cancer cells, inhibition of expression 
decreased proliferation.74 Heightened expression was also observed in head and neck 
cancer cells.66 
Fut 7 In hepatocarcinoma and colon cancer cell lines, upregulation was linked to heightened 
metastatic potential.77-79  





 Fut 8 
Heightened expression in hepatocarcinoma cell lines was linked to multidrug resistance, 
metastasis and proliferation.64, 80, 81  
 
In addition to their roles in cancer, human fucosyltransferase 7 (FUT7) has also been found to 
mediate the initiation and progression of Atherosclerosis, and FUT2 polymorphisms lowering its 
expression have been implicated in susceptibility to Crohn’s disease and asthma.82-84Notably, 
many other diseases involving aberrant fucosyltransferase activity are of pathogenic origin. 
There are two primary ways this occurs; in the first, the infectious pathogen activates host 
fucosyltransferase genes to increase infectivity and possibly immune evasion. For instance, T-
cell leukemia retrovirus activates FUT7, increasing sLeX expression to colonize the skin.85 
Likely to similar ends, Herpes virus specifically activates FUT3, FUT5 and FUT6 expression, 
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leading to increased sLeX production in infected hosts.82, 86, 87 A slew of human 
fucosyltransferase genes are also transcriptionally activated by cytomegalovirus, Varicella-zoster 
virus.86, 88 A virus or pathogenic organism can also encode their own fucosyltransferases.  
Of particular interest to some- perhaps the 50% of humanity by which it is infected- is the 
gram-negative Helicobacter pylori, listed as a carcinogen by the World Health Organization and 
the International Agency for Research on Cancer. It is at the cause of peptic ulcers and can result 
in the development of mucosa-associated lymphoma and gastric adenocarcinoma.89, 90 The 
mimicry of host surface glycans such as sLeX and LeX (Lewis X) by H. pylori has been found to 
play a key role in colonization and adhesion to the host environment.89, 91-97 As such, the 
inhibition of H. pylori fucosyltransferases such as FucT (a bacterial α(1,3)-fucosyltransferase), 






1.2. Assays for Glycosylation and its Inhibition 
 
1.2.1. The challenges of glycosylation assays 
 
The search for inhibitors for glycosyltransferases such as FucT begins with the 
development of a glycosylation assay. Many glycosyltransferases require a metal ion, often 
Mg2+ or Mn2+, to act as catalysts before the sugar-nucleotide donor can bind and the 
substrate or ligand molecule is accepted.98 As such, there are four core components to an 
assay: (1) the glycosyltransferase, (2) the metal ion, (3) the nucleotide sugar donor, and (4) 
the acceptor glycan.  
Developing assays to study or monitor for the occurrence of these reactions presents 
some challenges. On the whole, the number of binding site interactions with low-to-high 
affinities and the many components involved can complicate assay development.99 
Furthermore, to report the adequate signal type and strength for the assay’s platform of 
choice, additional components and reactions may need to be coupled to the addition of a 
sugar to a glycan substrate in a glycosylation reaction. Ex-vivo, glycans can be identified 
by immunohistochemistry- though antibodies are not specific to one glycan, but rather 
report a range of glycans.100, 101 Many other possible strategies have been employed in 
vitro. Lastly, some of the four core components of a glycosylation assay can be themselves 
difficult to obtain for an in vitro assay. 
It is difficult to obtain sufficient amounts of human glycosyltransferases  for in vitro 
testing, as these often suffer from lowered activity, low concentrations within the proteome, 
and a heterogeneity that makes them notoriously difficult to acquire and purify, alongside 
the additional issue of low half-lives.102-104 To express these, yeast (ex.: Pichia pastoris), 
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insect (ex.: Spodoptera frugiperda), and mammalian cell (ex.: chinese hamster ovary) lines 
are preferentially used for their compatibility with eukaryotic codon profiles and ability to 
perform the relevant post-translational modifications. The differences between the 
glycosylation pathways between these recombinant organisms have prompted efforts to 
‘humanize’ these cell lines.105-109 Eukaryotic cells have lower protein synthesis and folding 
rates than in prokaryotes, and mammalian cells are also more fragile, with lower growth 
rates.110, 111 When it comes to bacterial glycosyltransferases such as FucT, which can be 
produced using E. coli, the material cost and labor intensivity is lower than for human 
fucosyltransferases for which yeast is employed for production. 
Another component of glycosylation assays that can be difficult to obtain are the 
acceptor glycans. The inherent variability of glycosylation in organisms results in 
heterogenous mixtures of subtly different glycans that are difficult to distinguish and purify, 
which makes cells a poor factory for specific glycans. To obtain them, an in vitro approach 
is preferred: with either (1) solid-phase synthesis reactions or (2) one-pot chemoenzymatic 
reactions. Solid-phase synthesis is a laborious chemical process, especially when it comes 
to longer glycans such as oligosaccharides. For every monosaccharide unit to be added to 
a template molecule, protecting groups must be added and removed (i.e., deprotected) in 
sequential reactions before glycosylation is achieved.112 Since 1971, however, many tools 
and protocols such as oligosaccharide-to-polymer-support linkers, specialized glycosyl 
donors, and resin washes between steps have been created to further enhance, diversify, 
increase specificity, and automate this process.112 
The innate biological ability of glycosyltransferase enzymes offers an attractive 
alternative to chemical synthesis in their efficiency as a tool, once they are either discovered 
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or engineered for that glycosylation reaction. Called ‘one-pot chemoenzymatic synthesis’, 
this less laborious technique employs an ever-growing repertoire of characterized 
glycosylation and glycoside-hydrolase proteins to synthesize myriad glycans with growing 
ease.113, 114 The genes encoding these enzymes are often sequenced and cloned in a plasmid 
expression vector for expression in a bacterial or yeast production strain. Whilst new 
glycosyltransferases continue to be discovered and characterized from all domains of life, 
many improved enzymes have been engineered to facilitate the choice of glycosylated 
products for use as  acceptor glycans in assays, or other applications. 
To date, there is no standardized method to assay for glycosylation, but many assays 
require additional components so as to enhance the reporting signal, such as the use of 
tryptic peptides in MALDI-TOFMS spectrometry for the ion enhancement of glycans in 
femtomole concentrations and simultaneous ion suppression of peptide ions.115 Other assay 
designs have paired glycosylation to a type of reporter signal separate from the glycan’s 
chemical or structural properties, such as absorbance, fluorescence, or fluorescence 
polarization. 
 
1.2.2. Overview of approaches to inhibition assays for α-(1,3)-
fucosyltransferases 
The transition-state for fucosyltransferase involves four components: a divalent metal and 
nucleotide-sugar donor must work in concert with the acceptor substrate, both of which 
fucosyltransferase suffers a low affinity for.116-118  This has prompted the development of a 
myriad of differing strategies to efficiently assay for the inhibition.  
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To search for inhibitors of human fucosyltransferases, compound libraries have been tested. A 
high-throughput study which yielded many potential inhibitors of Fut6 and Fut7, for example, 
screened the Maybridge Hitfinder Collection (comprising 16,000 drug-like compounds at the 
time of the study) by monitoring for fluorescence polarization upon the addition of chemically 
synthesized fluorescein-tagged analog donor substrates to CMP-NeuAc and GDP-Fucose, to the 
commercially available glycoprotein fetuin.119 Due to the large size of fetuin, fluorescence 
polarization readings were made possible. This method was successful in finding inhibitors with 
a low (6%) rate of false positives. 
Another study with extensive work screened a focused compound library derived from sugar 
nucleotides for inhibitors of Fut6 by MALDI-TOFMS-based monitoring of glycosylation of 
specially designed and synthesized acceptor glycans. To have their glycosylation reliably 
detected by MALDI-TOFMS, these glycans were modified for higher ion-sensitivity by tagging 
them with tryptophanylarginine and stable isotope.120   
Monitoring by TLC has also been employed as a manner of detecting fucosylation.121 In that 
study, three compounds isolated from the fungal organism Stachybotrys cylindrospora were 
screened for their ability to prevent the fucosylation of LacNAc by Fut6.  
Another approach that has been used to detect this reaction is a pyruvate kinase/lactate 
dehydrogenase coupled-enzyme assay. In this assay, inhibition of Fut6 was detected for the 
fucosylation of LacNAc through a fluorescence reading, which indirectly measures the amount 
of GDP byproduct resulting from fucosylation with GDP-fucose. First, pyruvate kinase produces 
pyruvate from phosphoenolpyruvate and GDP, then lactate dehydrogenase uses NADH in 
solution to produce lactate from pyruvate.122 This results in a fluorescent signal inversely 
17 
 
proportional to the amount of GDP in solution, which itself is a measurement of how much 
GDP-fucose has been consumed by fucosylation.  
While these assays have yielded potential candidate inhibitors,  assay components and the 
libraries of potential inhibitors themselves are often expensive or otherwise difficult to obtain. 
Lowering the quantities required to perform assays as well as increasing the sensitivity are 
advantages that microfluidics can address. 
 
1.3. Microfluidic Devices  
1.3.1. Introduction to microfluidics platforms 
 
A relatively recent field, microfluidics is described by the use of micro to pico-volume 
fluid handling systems for applications ranging from point-of-care medical diagnostics to the 
directed evolution of enzymes and microorganisms.123-126 PubMed lists more than 3000 
publications with the “microfluidics” keyword published last year. According to a search on 
fluidicmems.com, an impressive 274 microfluidics companies are currently in existence. As the 
next step in the miniaturization and automation of laboratory protocols, microfluidic devices are 
often described as ‘labs-on-a-chip’. The throughput, materials, and cost of machinery involved 
differ between platforms (paper, droplet, channel and digital microfluidics) with continuous 
advances made which further lower their cost, already undercutting micro/nano fluid handling 
systems in price.   
All microfluidics platforms benefit from reduced volumes. The conservation of reagent is 
important when these are difficult or costly to obtain, as it is for many chemically synthesized 
potential pharmaceuticals, or in limited availability such as blood samples from newborn infants, 
which can only be collected at a precious low volume; without conservative use per test, they 
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may not be able to subject it to every test needed. Besides the conservation of reagent, the 
heightening of surface area to volume ratio is another one of the boons of working at reduced 
volume; it accelerates heat transfer and mass transfer rates, resulting in the greater efficiency of 
exo- and endothermic reactions.127, 128 The increase of surface-area-to-volume ratios has long 
been a method of engineering the enhancement of biosensors and reaction cells for various 
applications.129-132 
Channel microfluidics is the most widespread method in which microchannels are 
suffused with fluid and subjected to flow via syringe pumps or another pressure gradient. Given 
the small diameter of the channels (~1 µm), flow is dominated by viscosity. This creates laminar 
flows characterized by low Reynold’s numbers in which multiple fluid streams can flow in 
parallel within the same channels. Though the reliance on valves requires considerable expertise 
to fabricate and maintain, this system’s advantages lie in multiplexing and high-throughput 
application, the increased resolution of separation granted by capillary gel electrophoresis, as 
well as the simulation of in vivo conditions such as blood vessels using synthetic vascular 
networks.133-136 
Another popular microfluidics technique is droplet microfluidics, similar to channel 
microfluidics but with the automated generation of oil/water droplets in water/oil channels, often 
passively by junctions. These droplets are pinched off as the droplet volume exits the channel by 
the interruption of its flow by the volumes flowing out of adjacent channels. This allows for the 
ultra-rapid generation of droplets for high-throughput applications (10-100 kHz). Each droplet is 
analogous to a test tube, especially in systems that can perform operations downstream of droplet 
formation such as the sorting or merging of droplets to perform a reaction.137-139 
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 Much like Thin-Layer Chromatography (TLC), paper microfluidics requires a minute 
amount of substrate to be introduced to a paper device, which can be three-dimensional, connect 
multiple devices, and easily fabricated or modified for different adsorptive or absorptive 
properties.140, 141 Paper microfluidics enjoys lower material costs than other microfluidics 
techniques, but is less integrable with certain applications that would demand responsive 
automated operation (ex.: sorting), the preservation of certain kinds of degradable samples, or 
assays with non-colorimetric output readings. Since its conception, many point-of-care 
diagnostics devices have been developed using this technology, which does not rely on any 
electronic components and can easily be transported to locations that are distant from any 
labs.142, 143   
Among the different microfluidic platforms, Digital MicroFluidics (DMF) alone allows 
for the individual addressability of discrete on-chip volumes (droplets) — seeing as one may 
move, split, merge, mix and dispense any droplet on demand, each droplet on the device could be 
processed differently based on one’s desired need at every step of an experiment. DMF also 
enjoys ease of integration with standardized or homebrew software144, 145 and affordable 
electronics that can rapidly generate and respond to feedback based on visual, temperature, and 
electric signals among others145-148, enabling DMF to exhibit an unparalleled potential for 
intelligent automation. DMF has already been successfully explored as a miniature and cost-
effective platform for enzymatic, immune, and DNA-based assays.149-153  
1.3.2. Enzymatic assays on digital microfluidic devices 
 
DMF devices have long been developed for a variety of enzymatic applications. 
Operations held on DMF devices include a three-enzyme pyrosequencing protocol which was 
used to successfully sequence a 229 base-pair Candida parapsilosis sequence with 100% 
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accuracy.154 DMF devices have also been employed for the study of enzyme kinetics with 
alkaline phosphatase and fluorescein diphosphate, yielding values in accordance with the 
literature at a higher accuracy and while consuming less reagent.155 The digestion of proteins by 
either trypsin or pepsin enzymes has also been performed with trypsin and pepsin immobilized to 
miniature agarose discs formed on DMF devices.156 DMF has not only shown itself to be a 
platform suitable for enzyme assays, it also offers several advantages aside from those granted 
by individual addressability and automation. 
Notably, the reduced volumes of droplets allow faster heating and cooling of samples in 
temperature-variable assays, increasing the speed at which they can be performed.146 Time-
efficiency is further increased by the faster rate of enzymatic reactions which has been observed 
for DMF droplets.157 This is often attributed to the large surface area to volume ratio of small 
volumes, whose associated faster rates of mass and heat transfer can result in sped-up enzyme 
kinetics.137, 158 Another reason that assays can be sped up in DMF is due to the heightened 
concentration of substrates that can be used when these are of a precious or limited volume. This 
has been the case for an FDA-approved DMF device called SEEKER®, which is used to perform 
screens for lysosomal storage disorders.157 Capable of performing 5 enzymatic assays for up to 
48 samples, they estimate that while conventional methods could perform up to 10 tests per 
newborn blood sample, their DMF device can perform hundreds. Impressively, assays which 
took 20+ hours to incubate were reduced to 1 hour incubation times on the DMF device. These 
assays were all fluorometric in nature, using tools such as fluorescently tagged substrate glycans 
to report the hydrolytic action of enzymes involved in disease in a standardized manner for an 
automated, computer-controlled device. 
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 As for glycan-modifying reactions, there has been a DMF device by Martin et al., which 
quantifies the sulfonation of glycans performed enzymatically on-chip.159 Solutions in on-chip 
reservoirs, containing assay components, epimerase or one of three sulfosyltransferases, could be 
dispensed in order to sequentially glycosylate heparan sulfate. The assay was aided both by 
biotin-tagging the glycans so that streptavidin-tagged magnetic nanoparticles would bind to 
them, and by using the radionuclide PAPS 35S to attach a radioactive sulfate to the glycans so 
that sulfonation could be quantified by scintillation counting.159     
1.3.3. Types of digital microfluidic devices 
 
DMF devices exist in many forms, and while devices that employ acoustics, magnet-
based, or photonic methods of producing droplet motion are sometimes included under the 
umbrella of DMF, here we talk purely about devices based on ‘electrowetting’ and 
‘dielectrophoresis’.160-162 Just like paper microfluidics, some of these devices have been 
construed that can transport liquids across 3D planes of various shapes, though 2D devices are 
the most prevalent.163, 164 In either case, a one-plate or a two-plate configuration can be used. 
Both of these utilize metallized electrodes on a surface, much like an electrical circuit wherein 
every electrode is ‘off’ during device operation until it is ‘actuated’, meaning that it has been 
switched ‘on’ to a high-voltage state. These surfaces are then coated with a dielectric layer; this 
can be any non-conductive material, which can be polarized to induce electric fields. Some chips 
are then treated with a hydrophobic layer to ease the movement of aqueous liquids across its 
surface (ex.: Teflon). 
In a one-plate configuration, each electrode is accompanied by an adjacent ground 
electrode. This can complicate design steps, seeing as ground electrodes must be positioned such 
that droplets are in contact with both actuation and ground electrodes at all times during droplet 
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motion. Furthermore, exposed droplets are more prone to evaporation, and their electric fields 
are weaker, to the detriment of droplet movement and especially splitting and dispensing 
operations.165  
In a two-plate configuration, a top-plate is held above the chip, sandwiching the droplets 
between them. This not only helps in preventing evaporation, it functions as a continuous 
grounded electrode that spans every actuation electrode on-device. This top-plate is usually a 
transparent glass plate coated with indium tin oxide (ITO), which functions as the ground 
electrode and is biocompatible, nonetheless allowing visual monitoring of on-chip operations 
from above. As such, a two-plate configuration is more suited to performing the 
fucosyltransferase inhibition assay on-device as imagined, wherein on-device dispensing would 
permit the serial dilution of inhibitors to obtain a dose-response inhibition curve.  
 
1.3.4. Theory of droplet movement 
 
In DMF, droplet motion was long described as ElectroWetting-On-Dielectric (EWOD). 
The first instance of electrowetting-based actuation of liquid droplets for microfluidic application 
was reported in 2000 by Pollack et al.166 As a recent field, the theories behind its electromechanics 
and fluid dynamics have yet to be entirely elucidated. Here we present an overview of commonly 
used models and equations. 
Typically, volumes are deposited to the hydrophobic-coated surface of a device in the 
nanoliter to microliter scale. At rest, the large surface area to volume ratio of these small volumes 
minimizes inertial and body forces, allowing surface tension to become the dominant force. The 
study of fluid dynamics on electrowetted devices has resulted in the Lipmann-Young equation, 
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which describes the effect of applied voltages on the interfacial tension by the change in the angle 
of contact between the liquid interface and the surface upon which it rests. (Equation 1)  
Equation 1) Lipmann-Young equation 





In the Lipmann-Young equation, cosθv is the final contact angle, cosθ0 the starting contact angle, 
εi is the dielectric constant of the insulating layer (the combination of all layers between the droplet 
itself and the electrode), ε0 that of a vacuum, and γLG is the surface tension between the droplet and 
the medium around it (this can be air). While some have used contact angles to calculate driving 
force for droplet movement, that model is incomplete; even though increase of contact angle 
associated with droplet movement is reflected by Lippmann-Young for liquids with higher surface 
tension, it fails to apply to liquids who are themselves dielectric or who exhibit low surface tension, 
for which droplet movement can occur without significant contact angle changes.167, 168 This is 
because rather than being a result of a change in interfacial tension, droplet movement is a result 
of electrostatic pressure driven by excess charge at the three-phase contact line (droplet, 
surrounding medium, bottom/top plates).169 This discovery led to the emergence of the term 
‘Digital Microfluidics’, and many now prefer to refer to DMF theory by the electromechanical 




Figure 3) Electrostatic motion of a droplet on a digital microfluidics device 
Depiction of droplet motion by electrostatic forces induced upon the application of voltage 





Dielectrophoresis can be observed at the macro-scale. Just like a stream of tap water bends 
by the induced static charge in a comb, electrostatic force drives droplet motion: when an 
alternating potential is applied to an electrode, the electric field around it induce the alternating 
polarization of the dielectric layer above it. This dielectric layer insulates the droplet from being 
subjected to electric potential (allowing it to remain electroneutral) while inducing dipole moments 
for molecules in aqueous solutions, which are then drawn toward the area of high field strength – 
in other words, the actuated electrode.170-172 (Figure 3) The polarizability of particles in these 
droplets subjected to EWOD is given by the Clausius-Mossotti factor (Equation 2). 
Equation 2) Clausius-Mossotti factor 
𝐾(𝜔)  =
  𝜀𝑝
∗  −  𝜀𝑚
∗
  𝜀𝑝∗  +  2𝜀𝑚∗
  
The Clausius-Mossotti factor measures the polarizability of a spherical particle in a given medium, 
wherein K(ω) describes the Clausius-Mossotti factor with the angular frequency ω, ε*p describes 
the complex permittivity of the particle, and ε*m  the describes the complex permittivity of the 
medium.173, 174 The complex permittivity of each of these elements is determined by two of its 
properties: its dielectric constant, ε, and its electrical conductivity, σ. (Equation 3) 
Equation 3) Complex Permittivity 




In complex permittivity, ε represents the dielectric constant (also known as relative permittivity), 
σ is the electrical conductivity, ω is the field frequency, and i is the imaginary unit √-1. By inputting 
these complex permittivity values to obtain the Clausius-Mossotti factor, it is possible to calculate 
a dielectrophoretic force for a spherical particle in a given medium.170-172 (Equation 4) 
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Equation 4) Time-averaged dielectrophoretic force 
?̅?(𝑡) =  2𝜋𝑟3ε0ε𝑚𝑅𝑒[𝐾(𝜔)]∇|𝐸𝑟𝑚𝑠|
2  
The time-averaged dielectrophoretic force equation applies to spherical particles suspended in a 
medium, wherein F(t) is the time-averaged force exerted upon the particle, r is the particle’s radius, 
ε0 is the permittivity (or dielectric constant) of a vacuum, εm  is the permittivity of the medium, Re 
is a mathematical symbol designating that the real part of the following imaginary number must 
be used, K(ω) is the Clausius-Mossotti factor, and Erms is the root mean-square electric field. This 
has been used before to calculate the dielectrophoretic motion induced for E. coli cells by the 
actuation of electrodes in a liquid-immersed device, allowing precise cell sorting to distinguish 
between phenotypes of a bacterial population.175  
However, this only describes the force exerted on suspended particles and does not directly 
translate into droplet motion in DMF; to do so, one must take into account surface tension and 
electric-field determinants such as the frequency of the applied voltage. The predominant model 
used to describe the driving forces of droplet motion in DMF is the electromechanical model. This 
model uses the frequency of the voltage applied and the droplet position to calculate the total 
energy of the system, from which force can be derived.176 (Equation 5)   




















F is the horizontal force acting on a droplet on a two-plate DMF chip, ε0, εt, εd, and εp are the dielectric 
constants/permittivity of vacuum, the hydrophobic layer, the droplet’s media, and the dielectric 
layer respectively. y is the width of the electrode, and d’, D and d are the heights of the hydrophobic 
layer, the gap between the two plates, and the dielectric layer, respectively. Finally, v, v0, v1, v2 
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and v3 are, respectively, the voltages between the top-electrode and top-hydrophobic layer, top-
hydrophobic layer and droplet, droplet and bottom-electrode, top-hydrophobic layer and filler 
medium, and filler medium and bottom-electrode. 
From this model, the critical frequency, fc, can be obtained, which can be used to predict 
whether or not droplet movement can occur.176 (Equation 6) 
Equation 6) Critical frequency from the electromechanical force model for two-plate DMF 
𝑓𝑐 =  
𝑔𝐿(𝐶𝑝𝑡 +  𝐶𝑡)




fc describes the critical frequency in Hz,  gL is the conductance of the droplet, CL is its capacitance, 
Cpt is the total capacitance added together from the layers between the droplet and the bottom 
electrode, and Ct refers to the same, but between the droplet and the top electrode (ITO layer on 
the top-plate).  
In a study by Chatterjee et al. using similar DMF materials, frequencies ~8 kHz were used at 
a driving voltage of 100 VRMS to move aqueous liquids.
176 However, protein-rich solutions such 
as those used for an enzyme inhibition assay exhibit higher viscosity and hydrophilicity, which 
both impact the ease of movement for the droplet. Higher frequencies in the 10 kHz-15kHz range 
should then be used; when inserting this range into the equation for force given by the 
electromechanical model (Equation 5), with Teflon as the hydrophobic layer, parylene-C as the 
dielectric, and air as the medium between two plates, possible driving voltages for performing the 




1.3.5. The challenges of DMF 
 
Still in early development, many aspects of DMF materials and design remain to be 
engineered to achieve their full potential. Some of the challenges in the continued development of 
DMF technology for screening involve increasing throughput148, minimizing dielectric 
breakdown177, 178, and reducing the chance of electrode fouling when handling protein-rich 
solutions.179, 180  
Much like the visual display revolution that occurred when LCD displays were invented, 
many are working on increasing the throughput of DMF by packing more into less. Just like how 
a pixel in LCD displays is the vehicle for one color at a time, each electrode in DMF is the vehicle 
to carry one sample- and like how the number of pixels in an image contributes its detail and 
complexity, the number of electrodes on a device influences the complexity of the experiments 
that can be held, as well as their throughput. Technologically, DMF is already inherently scalable, 
as one needs only include more switches and/or increase device area to add more electrodes- but 
another approach to increasing DMF throughput is to minimize the size of each electrode, which 
can be achieved by polishing fabrication techniques, and to decrease the number of switches 
needed for an electrode array by engineering more advanced switches and circuitry. 
To minimize dielectric breakdown, in which the insulating layer is worn down between the 
electrode and droplets resulting in burns to the device, typically a balance is struck in selecting a 
dieletric layer height that is thin enough to provide a strong electric field to influence droplet 
movement while being thick enough not to wear down too fast for a device to complete its tasks.176 
This can be further improved by selecting stronger dielectric materials or by reducing the voltages 
(and thus, the strength of the electric fields) necessitated on devices by improving other factors 
affecting droplet motility, such as hydrophobicity. 
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This can also address another of the significant challenges in DMF, biofouling. This occurs 
when proteins adsorb to the surface of a device, preventing any further movement across those 
areas. This can be circumvented to an impressive degree by the addition of DMF surfactants and 
oils. The expansion of this repertoire of additives continues, driven by the need for surfactants 
compatible with various experimental needs. 
Concerning assays that involve many separate steps of component addition, the consistency 
of dispensed droplet volumes is pivotal. Dispensed droplet volumes and their reproducibility can 
vary based on multiple factors; the viscosity of the solution, gap pitch and height, ratio between 
volume in the reservoir and volume on the destination electrode, electrode size and shape, number 
of serial electrodes in the liquid finger, interfacial tension, and the speed of sequence actuation, 
among others.181-183 If volumes dispensed on-device differed, so would the concentrations of assay 
components in each sample. Specifically for inhibition assays, the ability to obtain inhibition 
curves is a critical component used to compare the cost and viability of inhibitors, which usually 
requires concentrations spanning orders of magnitude. 
As DMF continues to be characterized, developed with optimized materials, and integrated 
with other hardware, and as software is eventually written to be universally applicable to any DMF 





Chapter 2. Thesis Objectives 
 
The thesis objectives are; first, to test a hypothetical fucosyltransferase inhibition assay 
using a synthetic fluorescently labelled disaccharide, MU-β-LacNAc. Secondly, to implement this 
assay on a microfluidics device.  
 
2.1. Testing a hypothetical inhibition assay using a synthetic fluorescently 
labelled disaccharide, MU-β-LacNAc 
 
Toward a future goal of screening for potential inhibitors of fucosyltransferases, a 
fluorescence-based inhibition assay was developed for the fucosylation of the labeled synthetic 
disaccharide, 4-methylumbelliferyl β-N-acetyllactosaminide (MU-β-LacNAc). MU-β-LacNAc 
does not fluoresce in itself. Upon treatment with the glycoside hydrolase enzymes including the 
β-galactosidase from S. pneumoniae (BgaA), which catalyzes the hydrolysis of terminal LacNAc 
on oligosaccharides184, and N-acetylhexosaminidase from S. plicatus (SpHex), which hydrolyzes 
the remaining terminal GlcNAc185, fluorescent 4-methylumbelliferone (4-MU) is released 
(Figure 4). However, fucosylation of the labeled oligosaccharide prior to this treatment results in 
a structure that is not recognized by the glycosidases, preventing hydrolysis and the subsequent 
fluorescent signal. As such, when the fucosyltransferase is inhibited, the first case in which 





Figure 4) Schematic of MU-β-LacNAc Inhibition Assay 
Depiction of the interactions between assay components in conditions with or without inhibitor. 
In the first case, (top), glycoside hydrolases β-gal from S. pneumoniae (BgaA) and N-
acetylhexosaminidase from S. plicatus (SpHex) sequentially cleave fluorogenically tagged 
disaccharide, MU-β-LacNAc, into its monosaccharide components, releasing fluorescent 4-
methylumbelliferone (4-MU). In the second case, (bottom), BgaA and SpHex do not recognize 
their target, seeing as it has been fucosylated. 
 
 
2.2. Implementing the Fucosylation Inhibition Assay on a DMF Device 
 
The next thesis objective involved multiple aspects. First, DMF devices had to be designed, 
fabricated and tested which could (1) perform serial dilutions on-chip, (2) perform the entirety of 
the assay on device, and (3) incubate enough samples to produce an inhibition curve of sufficient 
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range to report IC50 values. Besides developing a DMF design with novel electrodes, DMF 
software, and analytical methods which were then validated, implementation of the assay on the 
DMF device also entailed making changes to optimize solutions and conditions for this platform 
regarding droplet movement and the addition of surfactants and oil to assay reagents. These 
changes were also validated in a series of tests, finally leading to IC50 curves for proof-of-
concept (GDP) inhibitor in a 384-well plate and on a digital microfluidics (DMF) device. Here, 
we introduce the integration of a fucosyltransferase enzyme inhibition assay on DMF using an 
oil-core and air medium. To our knowledge, this setup is only described in two studies;186, 187 and 
although both of these systems were characterized, no biological application was presented or the 
range of tested concentrations was minimal (only ~one order of magnitude). Here, we describe 
the first fucosylation inhibition assay performed on DMF using an oil-core with air configuration 
along with generated proof-of-principle results, showing tested concentration of multiple orders 
of magnitude for the first time, followed by a comparison to gold-standard techniques (e.g., 384-




Chapter 3. Methodology 
 
In this chapter, the reagents and materials, as well as the methodologies employed for both 
the biological and engineering aspects of this project are described in detail. 
 
3.1. Reagents and Materials 
 
 
Unless specified otherwise, general-use chemicals and kits were purchased from Sigma-
Aldrich (St. Louis, MO). Competent E. coli BL21(DE3) strains were stored at -80 °C before 
transformation procedures. Four plasmids were used in this study: pET29-Abg2F6, pET28-BgaA, 
pET3a-His6-SpHex, and pET21-FucT. Media formulations included 1 L volumes of LB media 
were prepared with 1 % w/v tryptone, 0.5 % w/v yeast extract and 0.5 % w/v NaCl, then sterilized 
by autoclave. 100 mL SOC media was prepared by the addition of dry stocks to these final 
concentrations: 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 2% tryptone, and 
0.5% yeast extract, after which the solution was sterilized by autoclave. Glucose was sterilized 
through a 0.22 µm syringe filter and added to the SOC media to a 20 mM final concentration. 
Ampicillin plates were prepared in 10 cm petri dishes with 500 mL LB media with the addition 
7.5g agar and 50 µg/mL kanamycin. 100 mM GDP solutions were prepared by dissolving 44.3 mg 
in 1 mL ddH2O. 1 M pH 7.5 Tris buffer was prepared by dissolving dry solid Tris in ddH2O and 
adjusted to pH 7.5 with the dropwise addition of concentrated NaOH. 500 mM, pH 8.0, EDTA 
buffer was prepared by dissolving dry solid in ddH2O with constant stirring on a slightly heated 
hot plate and gradual adjustment to pH 8.0 with the dropwise addition of concentrated NaOH. 100 
mM MgCl2 solution was prepared by dissolving solid MgCl2 in ddH2O. 5 mL 1 M HEPES buffer 
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was prepared by dissolving 1.192g dry solid in 4 mL ddH2O, then adding concentrated NaOH 
dropwise to pH 7.0. 1 mM GDP-Fucose solution previously synthesized by Dr. Ching-Ching Yu 
and Teng-Wei Tsai at the Chemistry Department at National Chung-Cheng University in Taiwan, 
was also prepared by dissolving solid in ddH2O. Solutions used for the fucosylation assay consisted 
of 80 mM GDP solution, 0.135 mg/mL FucT solution, reaction initiating ‘Glycosylation’ solution 
(40 mM MgCl2, 0.04 mM MU-β-LacNAc, 0.08 mM GDP-fucose), and hydrolytic ‘Hydrolysis’ 
solution (125 mM EDTA, 0.25 mM BgaA, 0.25 mM SpHex). All solutions were prepared with 
either 50 mM Tris (Proof-of-principle) or 25 mM HEPES buffer (other). With GDP:FucT: 
‘Glycosylation’:‘Hydrolysis’ volumes in the ratio 2:1:1:1, the highest concentration of GDP at the 
time of the reaction was 40 mM, concentrations in  ‘Glycosylation’ mix were at (10 mM MgCl2, 
0.01 mM MU-β-LacNAc, 0.02 mM GDP-fucose), and concentrations of ‘Hydrolysis’ components 
at the hydrolysis step were of (25 mM EDTA, 0.05 mM BgaA, 0.05 mM SpHex). Except for the 
proof-of-principle experiments, minutes before the assay, 0.05% Pluronics F68 was applied to 10-
12µL aliquots of each solution.  
Microfluidic device fabrication reagents and supplies included chromium-coated glass 
slides with S1811 photoresist from Telic (Valencia, CA), indium tin oxide (ITO)- coated glass 
slides, RS =15-25 (cat no. CG-61IN- S207, Delta Technologies, Loveland CO), FluoroPel 
PFC1601V from Cytonix LLC (Beltsville, MD), MF-321 positive photoresist developer from 
Rohm and Haas (Marlborough, MA), CR-4 chromium etchant from OM Group (Cleveland, OH), 
AZ-300T photoresist stripper from AZ Electronic Materials (Somerville, NJ), DuPont AF from 
DuPont Fluoroproducts (Wilmington, DE). Transparency masks for device fabrication were 
printed from CAD/Art (Bandon, OR) and polylactic acid (PLA) material for 3D printing were 
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purchased from 3Dshop (Mississauga, ON, Canada). De-ionized (DI) water had a resistivity of 18 
M•cm at 25 °C.  
 
3.2. Transformation of Abg2F6, BgaA, SpHex and FucT expression strains 
 
After thawing on ice, cells of E. coli BL21(DE3) were incubated in separate 2 mL Eppendorf tubes 
into which pET29-Abg2F6, pET28-BgaA, pET3a-His6-SpHex, or pET21-FucT was added (see 
Fig. S1 for plasmid maps). A negative control tube contained cells and a plasmid without the gene 
insert (e.g., pET28). Before transformation, cells were kept on ice for 5 min, then heat shocked at 
42°C for 45 s and returned to ice for 2 min. 1 mL of SOC media was added to each tube, after 
which cells were heat shocked at 42°C for 45 s and returned to ice for 2 min again. After 1 h of 
incubation at 37°C, the tubes were centrifuged at 14,000 x g for 1 min. 100-200 μL of the 
transformed cells were plated on the LB-agar plates prepared with the appropriate antibiotic 
selection marker. Plates were left in the incubator at 37°C overnight and colonies were counted 
after 24 h. 
 




Colonies of E. coli BL21(DE3) transformed with pET29-Abg2F6, pET28-BgaA, pET3a-His6-
SpHex or pET21-FucT were picked from their plates and used to inoculate 4 mL volumes of LB 
containing 100 μg/mL of their respective antibiotics. Each starter culture was grown overnight at 
37°C with shaking at 220 rpm. 400 mL LB was then inoculated with 4 mL of starter culture and 
grown in the same conditions for 2-5 hours at 37°C until OD600 reached ~0.6, at which point 
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protein expression was induced with 0.1 mM IPTG. BgaA and FucT were expressed overnight at 
30°C and SpHex at 25°C, all with shaking at 220 rpm. 
Cells were harvested by centrifugation (10,000g, 4°C, 15 minutes), then resuspended in 
lysis/wash buffer (For BgaA and SpHex: 50 mM Tris; 500 mM NaCl; 7.5 mM imidazole; pH 8. 
For Abg2F6: 20 mM Tris; 500 mM NaCl; 5 mM imidazole; pH 8. For FucT: 35 mM Tris; 500 
mM NaCl; 7.5 mM imidazole; pH 8). Cell suspensions were frozen at -20°C before purification 
could resume. 
After thawing on ice, Lysozyme, DNAse I, and RNAse A were each added to 5 μg/mL. 
For each protein, one half of a Roche protease inhibitor tablet (Sigma-Aldrich, Inc.) was 
dissolved in 500 μL deionized water and then added. Cells were lysed by sonication (Amplitude 
25%; Pulse on 5s; off 15s; total time 3 minutes) then centrifuged at 4°C with 15,000✕g for 30 
minutes. 0.22 μm syringe filters were used to filter each supernatant. 
After using 10 mL lysis/wash buffer to equilibrate the 1mL Thermo Scientific™ 
HisPur™ Ni-NTA Resin cartridges, filtered protein lysates were added to the cartridges and the 
lysate flow-through collected for later analysis with SDS-PAGE. Once again, 10 mL lysis/wash 
buffer were added and the wash flow-through collected. 
FPLC was performed with an Äkta FPLC System and an increasing imidazole gradient (0 
mM to 400 or 800 mM) over 30 mL, collecting thirty 1 mL fractions. This was achieved by 
gradually increasing the ratio of elution buffer to lysis/wash buffer being pumped into the 
cartridge. The elution buffers used for BgaA, SpHex and FucT were identical to their lysis/wash 
buffers with the addition of 400 mM imidazole (BgaA and Abg2F6) or 800 mM imidazole 
(SpHex and FucT). Lysis/wash and elution buffers were degassed before use. Fractions were 
stored at 4°C. 
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After collecting fractions of interest identified by peaks in UV absorbance at 280 nm, SDS-
PAGE was performed to identify fractions that contained the protein of interest by their bands 
(Abg2F6 ~51 kDa; BgaA ~99 kDa; FucT ~55 kDa; SpHex ~55 kDa). Each selected fraction was 
visually assessed to be ≥95% pure. Selected fractions for the same protein were pooled together. 
Pooled samples were concentrated by centrifugation with Vivaspin® 20 concentrators to <0.5 
mL by spinning at 4200✕g for 16-43 minutes at 4°C. 10DG Desalting columns (Bio-Rad) were 
equilibrated with 20 mL storage buffer (20 mM Tris, 150 mM NaCl, pH 7.5 for Abg2F6, BgaA, 
SpHex, and 25 mM Tris, 150 mM NaCl, pH 7 for FucT). Concentrated protein samples were 
buffer exchanged with storage buffer using the equilibrated 10DG Desalting columns according 
to the manufacturer specifications and stored at 4°C and -20°C.  
Protein concentrations were quantified by BCA assay using the Pierce™ BCA Protein 




3.4. Enzymatic Synthesis and Purification of MU-β-LacNAc 
 
 
Figure 5) Synthesis of fluorogenic 4-MU tagged oligosaccharide 
MU-β-LacNAc one-pot chemoenzymatic synthesis using the mutant Agrobacterium 
glycosynthase Abg2F6 to catalyze the addition of a Galactose sugar unit from an α-GalF 
donor to MU- β-GlcNAc, resulting in a fluorogenic 4-MU tagged LacNAc molecule.  
 
 
Mutant glycosynthase Abg2F6 from Agrobacterium sp. from a directed evolution 
experiment by Kim et al. was obtained.188 As in previous work by Kwan et al., Abg2F6 was used 
in vitro to chemoenzymatically synthesize MU-β-LacNAc from 4-methylumbelliferyl N-acetyl-β-
D-glucosaminide (MU-β-GlcNAc) and αGalF50 (Figure 5). Briefly, the reaction was performed at 
room temperature with a solution containing 2.7% DMSO, 0.1 mM MU-β-GlcNAc, 4 mM αGalF, 
and 0.5 mg/mL Abg-2F6 in 50 mM pH 7.15 potassium phosphate. Potassium phosphate buffer 
was prepared to pH 7.15.189 The reaction was set on a rotating tube rack for 48 h, after which Thin 
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Layer Chromatography (TLC) was performed to assess the presence of new product. Spots were 
visualized and circled in pencil under a long-wave UV light lamp, then stained by treatment with 
p-Anisaldehyde. TLC spots were identified by comparing them to those reported previously, for 
which NMR characterization had been previously performed.190 SpHex was added to the solution 
so as to hydrolyze remaining Glc-NAc. TLC analysis confirmed that the spot attributed to Glc-
NAc had been removed. Column purification was performed with a C18 Hypersep™ hydrophobic, 
reverse phase column (Thermo Scientific™), washed with methanol prior to equilibration with 
dH2O. The MU-β-LacNAc reaction mix was added, after which 3 fractions were eluted with just 
dH2O, then 11 fractions were eluted with increasing concentrations of MeOH by 5% increments. 
It was observed by TLC that the fractions at 30% MeOH and to a lesser degree, 35% MeOH 
contained the spot corresponding to MU-β-LacNAc; however, a spot thought to be 4-MU impurity 
was still present on both.   
Rotary evaporation was performed with a 40°C water bath gently evaporated MeOH and 
H2O from the sample.  
Liquid-liquid extraction with Ethyl Acetate was used to further purify the sample; 
residual 4-MU was separated into the organic Ethyl Acetate layer while MU-β-LacNAc was 
retained in the aqueous layer. TLC verified that high purity was achieved after 4 extractions. 




3.5. Fucosylation Assay in Well Plates 
 
 
To generate inhibition curves in a well plate, a blank (0 mM GDP) and 6 GDP solutions 
were manually prepared in four-fold dilutions for their reaction concentrations to range from 40 
mM to 0.2 mM. These concentrations were assayed in triplicate, using multichannel 
micropipettes to simultaneously deliver volumes to the 7 samples (with different concentrations 
of GDP) of each replicate. The steps for each replicate were as follows, with each replicate 
started 30 seconds apart: (1) 5 uL FucT solution was added to 10 uL GDP solution and left to 
incubate for 5 minutes at room temperature. (2) 5 uL Glycosylation mix was added, followed by 
10 minutes of incubation at room temperature. (3) 5 uL Hydrolysis mix was added, followed by 
5 minutes of incubation at room temperature. (4) Fluorescence readings were taken. 
 
3.6. Fluorescence Readings  
 
3.6.1. Calibration in Well Plates 
 
A Clariostar® Monochromator Microplate Reader (BMG Labtech, Ortenburg, Germany) was 
used. 4-Methylumbelliferone (4-MU) fluorescence was measured with 40 flashes at λex: 360-20 
λem:450-30 in 25℃. Well-plate assays were conducted with Nunc™ 384-Well Polystyrene Black 
Microplates (Thermo Scientific™). These were utilized in low throughput, using their smaller 
(~25 µL minimum volume) wells to conserve volumes. Using freshly prepared 4-MU standards 
with concentrations spanning 2.5 to 25 µM, focal height and gain were optimized by the 




3.6.2. Reading Fluorescence from DMF chips  
 
 
Figure 6) Scan of the surface of a DMF chip mounted on a well plate with fluorescence 
intensity.  
Droplets represented are of a 4-MU standard with known concentrations from 0 μM (top left) to 
25 (bottom right) μM, pipetted onto the surface of the chip. Visualized in MARS (©BMG 
Labtech) data analysis software with a “rainbow” heatmap setting to represent RFU units from 
low (purple) to high (red). Selected fluorescence readings are highlighted by a square in the 
center of each droplet. 
 
DMF chip assays were scanned while mounted on the surface of the Nunc™ 384-Well 
Polystyrene Black Microplates. To obtain a composite fluorescence heatmap of the chip’s 
surface and droplets, a 96-square-well template was modified on the Clariostar® software to 
eliminate the gap space between wells. Each pixel represented one fluorescence reading (40 




3.6.3. Optimization of Settings 
 
 Focal Height was determined by scanning in 0.2 mm increments beginning from the 
height of the microplate (14.40 mm) until the droplets were no longer distinguishable from the 
chip by their fluorescent signal (17.9 mm). A favorable focal height was selected at 15.80 mm. A 
gain of 750, at which the lowest concentration of the 4-MU standard (2.5 µM) would be 
distinguishable, was chosen.  
3.6.4. Normalization and Analysis 
 
After optimizing settings, fluorescence heat maps could be obtained in the Clariostar’s 
MARS (©BMG Labtech) data analysis software. However, the fluorescence exhibited by certain 
elements on the chip, namely the double-sided tape used to hold the top-plate in position, was far 
above the highest droplet fluorescence readings. Only by using a rainbow gradient for 
visualization with a manually set upper threshold of 40000 fluorescent units out of the maximum 
signal, 260 000, was it possible to visualize droplet positions within the data, after which areas of 
interest could be selected before porting data to Excel. 
Analysis of DMF scans was done by taking the average of areas selected at the center of each 
droplet and zeroing them on the blank, defined as the average of background readings found at 
“empty” (no droplet) locations on a chip. In the case of pure water, readings were 




3.7. Automation Hardware Setup 
 
 
Figure 7) Automation system diagram 
Diagram of DMF hardware and its connectivity labeled with 1. Power Supply, 2. Amplifier, 3. 
Function Generator, 4. Control Boards, 5. Arduino, 6. Contact Apparatus, 7. DMF chip, 8. 
Camera, 9. Laptop  
 
 
The automation system consists of Python 2.7 softwares (described separately) used to 
control an Arduino Uno microcontroller (Adafruit, New York, USA). Driving input potentials of 
160-220 VRMS were generated by amplification of a square wave output from a function generator 
(Agilent Technologies, Santa Clara, CA) operating at 15 kHz by a PZD-700A amplifier, (Trek 
Inc., Lockport, NY) and delivered to the PCB control board. The Arduino controls the state of 
high-voltage relays (AQW216 Panasonic, Digikey, Winnipeg, MB) that are soldered onto the PCB 
control board. (Figure 7) The logic state of an individual solid-state switch is controlled through 
44 
 
an I2C communication protocol by an I/O expander (Maxim 7300, Digikey, Winnipeg, MB). This 
control board is mated to a pogo pin interface (104 pins), where each switch delivers a high-voltage 
potential (or ground) signal to a contact pad on the DMF device. See our GitHub registry 
(https://github.com/shihmicrolab/Automation) to assemble the hardware and to install the open-
source software program to execute the automation system. Droplets operations were visualized 
by a 3.0 MP CMOS Color USB camera (EO-3112C, Edmund Optics, New Jersey, USA) attached 
to a 10× C-mount close focus zoom lens (54363, Edmund Optics, New Jersey, USA).  
When switching an electrode on and in so doing, subjecting it to electric potential, the coating of 
parylene-C on the device acts as a dielectric layer allowing electrostatic force to induce the rapid 
movement of on-chip volumes without subjecting them directly to a voltage.191 Droplets were 
grounded via contact with an Indium Tin Oxide (ITO)-coated glass plate placed onto the chromium 
electrode-bearing bottom plate, joined by two layers of selectively placed double sided tape to a 








Figure 8) Photolithographic fabrication 
A DMF device at different stages of photolithographic fabrication in a clean-room. (1) A 
transparency printed with dark ink. (2) Exposure under UV light with a superimposed 
transparency solubilizes PGMEA to TMAH (3) After TMAH stripping and baking on a hot-
plate, photoresist only remains in the ink area of the transparency (4) Chromium Etchant 
strips the chromium oxide which is unprotected by photoresist (5) A different TMAH stripping 
solution is used to remove remaining photoresist (6) Silane is coated to aid parylene in 




Photolithography was used to fabricate DMF chips in a cleanroom. (Figure 8) The 2x3 
inch DMF design was prepared in AutoCAD. The transparency was printed by CAD/Art 
Services Inc. (Bandon, OR), with a minimum guaranteed feature size of 10 μm. 2x3 inch Glass 
slides metallized with chrome oxide and coated with AZ-1500 photoresist (1-methoxy-2-
propanol acetate, or PGMEA) were ordered from Telic Company (Valencia, CA). These were 
exposed together for 5 seconds to UV light. This solubilizes the photoresist, allowing it to be 
washed away in the next step. 
The solubilized photoresist was removed with MF-321 developer acquired from Rohm and Haas 
Company (Marlborough, MA). Etching was performed with CR-4 chromium etchant from OM 
Group Inc. (Cleveland, OH). AZ-300T from AZ Electronic Materials plc (Somerville, NJ) was 
used for stripping. 
DMF devices were primed for 15 minutes with 50:50:1 deionized water : isopropanol : silane 
solution, seeing as silane enhances the bonding of plastics such as parylene to silicates such as 
the glass surface of the chip. Contact pads on the DMF devices were then covered with heat-
resistant tape. The SCS Labcoter 2 PDS 2010 from Specialty Coating Systems Inc. (Indianapolis, 
IN) was used for the chemical vapor deposition of Parylene-C, after which further steps were 
performed outside of the clean room. 
CG-611N-S207 ITOs (Indium tin oxide coated glass slides) were acquired from Delta 
Technologies Limited (Loveland CO).  1% Teflon was prepared by baking dry pellets in FC-40 
from Sigma-Aldrich at 65℃ for 5 days followed by 0.22 μm syringe filter sterilization. A WS-
650 Spin Coater from Laurell Technologies Corporation (North Wales, PA) was used to apply a 
Teflon hydrophobic coating to both the device and the ITOs.  
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Two layers of double-sided tape were used to adhere the ITO to the DMF chip. Gap height was 
measured by caliper, subtracting the height measured for each of the individual plates from the 
total height measured where the two plates and the tape. 
48 
 
3.9. Design, Fabrication and Operation of Digital Microfluidics Devices  
3.9.1. Design and operation of chip 
 
Figure 9) Design of DMF Device 
Schematic of the electrode layout of the DMF design created to run the inhibition assay. The 
2x3 inch digital microfluidics chip design comprised 103 electrodes among which a waste 
collection electrode, two adjacent tracks connecting every section, and 10 reservoirs, 5 of 
which included pipetting inlets. A zoomed-in view of a skewed-wave electrode used on the 




As shown in Figure 9, the device layout designed in AutoCAD featured an array of 93 
actuation electrodes (9 types, various sizes) connected to 10 reservoir electrodes (2 variants, 4.1 x 
3 mm ea.), with an average of inter-electrode gap size of 30 m. Each electrode was connected to 
a square contact pad at the edge of the chip using 70 micron wide lines; when the devices were 
mounted, each of these contact pads would be in contact with a pin connected to the electrical 
setup.  
Aqueous solutions could be pipetted directly onto the reservoirs before the ITO was affixed to the 
chip. Removal and addition of volumes to device mid-operation was achieved by pipetting to one 
of 5 strategically exposed electrodes on the edge of the ITO. The electrodes, for which a third of 
the surface area is positioned under the ITO, could pull droplets underneath the ITO whenever 
actuated. (Figure 10) Generally, all droplets containing proteins were supplemented with 0.05% 
Pluronics F-68. The pipette tips used to dispense these volumes to the chip were first coated in 
silicone oil by pipetting the oil in and back out of the tips. Waste and unused fluids were removed 





Figure 10) Volume manipulations on DMF device 
Camera images of the types of operations (ex.: dispensing, mixing…) performed  
on the digital microfluidic device. 
 
Several types of sequences were made with the software for each location on the chip so 
that droplets could move, mix, or be dispensed on demand. These sequences were used to run the 
enzyme inhibition assay on-device, using the steps as described in Figure 11. 
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3.9.2. Fucosylation inhibition assay on a DMF device 
 
Figure 11) Illustrated protocol for performing the assay on-chip 
1-5: Serial dilution spanning up to 3 orders of magnitude within 5 dilutions. 6: Addition of 
Fucosyltransferase to inhibitor followed by 5+ minutes of incubation allowing the inhibitor to 
bind. 7: Addition of MU-β-LacNAc to the solution, which results in its fucosylation depending 
on the degree of inhibition attained in the previous step. 8: Introduction of a reaction stopping 
mix which consists of EDTA, SpHex and BgaA; EDTA to prevent further Fucosyltransferase 
activity, and the glycoside hydrolases to sequentially cleave unfucosylated MU-β-LacNAc into 
its monosaccharide components. 9: After 5+ minutes of incubation, chip scanned for 





To obtain inhibition curves from assays performed on-chip, DMF chips were used to 
prepare 6 GDP solutions for reaction concentrations ranging from 40 mM to an estimated ~0.008 
mM from performing serial dilutions of an estimated ~5.5-fold per step on-chip. All solutions 
had 0.05% pluronics F68 added to them prior to the beginning of the experiment, and pipette tips 
were coated in silicone oil before being used to dispense the solutions.  
A 28-step protocol was used (Figure 11).  The steps were as follows: (1) Five 2.7 uL 
droplets of 25 mM HEPES buffer were manually pipetted onto the reservoirs after which the ITO 
plate was placed on top of the device. (2) A 3.1 uL droplet of the inhibitor (i.e. 80 mM GDP) was 
added to the edge of the ITO (aligned with a reservoir electrode) and the droplet was loaded into 
the reservoir by applying a driving potential on the reservoir. (3) A one-unit droplet of GDP-
fucose (~ 500 nL) was dispensed from the reservoir. (4) The dispensed droplet was brought to 
one of the reservoirs already primed with 2.7 uL buffer and mixed twice (this was done by 
pulling the liquid out of the reservoir gradually along a linear path, then actuating the reservoir 
electrode to pull the entire volume back in one step.) This created an average serial dilution of 
~5.5-fold. (5) A unit droplet of the dilution was dispensed. (6-9) Steps 4-5 were repeated with 
the subsequent buffer-containing reservoirs to generate a total of five different inhibitor 
concentrations (~14.5, ~2.64, ~0.48, ~0.087, ~0.016 mM) in addition to the 80 mM starting 
concentration. (10) A 3.1 uL droplet containing the negative control (25 mM HEPES buffer, 
without inhibitor) was added to an empty reservoir (as in step 2). (11) Two one-unit droplets 
(~500 nL each) were dispensed from each of the 7 filled reservoirs and moved aside to merge 
into a two-unit droplet (~1 uL) and clear the way for the leftover volume droplet to exit the 
reservoir. (12) The leftover volume droplet was moved to the waste electrode, where it was 
wicked away by a paper strip and disposed of off-chip. (13-18) Steps 11-12 were repeated for the 
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other 6 concentrations of GDP (incl. 0 mM). (19) A 3.1 uL droplet of FucT was added to an 
empty reservoir (as in step 2) and a one-unit droplet was dispensed and mixed with the two-unit 
droplets containing inhibitor. (20-25) Step 19 was repeated for the other 6 concentrations of GDP 
(incl. 0 mM). (26) 5 or more minutes after step 19 for each droplet (+/- 1 minute between 
samples but all >5 min allowing the inhibitor enough time to bind), Glycolysis solution was 
added to each droplet (as in steps 19-25). (27) After 10 minutes of incubation, Hydrolysis 
solution was added to each droplet (as in steps 19-25). (28) After 5 minutes of incubation, 
fluorescence readings could be taken. (Occasional Steps) At any point during the run of the 
assay, when impurities were suspected on the common surface (main linear track) of the chip 
(ex.: a small residual droplet left on the track, dust having slid under the ITO), buffer was 
introduced to an empty reservoir (as in step 2) and used to wash the track before it was actuated 





3.9.3. Software setup  
 
Four software programs were used to execute the droplet operation protocols. 
ArduBridge.py, scripted by Guy Soffer, provided the framework for the Arduino to interpret 
actuation instructions and to switch the target pin(s) to its high voltage state for a specified time. 
This framework also used the pySerial.py open-source module192 to access the USB port and 
communicate with the Arduino. ArduBridge commands included setup.seq[‘x’].start(‘y’), in 
which x is the name of the sequence and y is the number of times to actuate it, and setup.stop(), 
which were inputted into the Python shell. 
Protocols and sequences were stored in a .py (Python) script in which users could define 
names, lists representing sequences of electrodes to actuate, the length of their actuation 
(‘onTime’), and the time between the actuation (‘period’) of each electrode or set of electrodes in 
a sequence. Users could use this script to customize and input their own additional functionality 
into ArduBridge. Here, a GUI was created (called LLGUI) to be used as an interface for 
ArduBridge, providing buttons for each sequence with which actuation script was copied to the 
clipboard for ease of input to the shell.  
A program called Pasemaker.py was created to construct electrode sequences for 
automation on any DMF design.  
 
3.9.4. Software operation: Running an assay-on-device 
 
While this only has to be done once, electrode actuation sequences must be prepared 
before running an experiment on-chip. To do this, one must first create a .csv (comma-separated 
values) file representing the layout of the chip’s electrodes. A csv file can be written in Notepad, 
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any script writing program, or programs that can save as csv (ex.: Microsoft Excel). The 
electrodes do not need to be listed in order, but if there is bussing on the design, each bussed 
electrode must be listed on a separate line/row (Figure 12). 
 
 













Diagram of the electrode layout of a sample device (left) comprising 10 electrodes and its 
corresponding input .csv files either written in a spreadsheet (center) or text editor (right).  
 
In a spreadsheet, each electrode is listed in the first column, and subsequent numbers in 
adjacent columns are the numbers of the electrodes connected to it. 
In a text file, each electrode is listed on a separate line, then the numbers of the electrodes 
connected to it are listed on the same line, separated by commas. 
PaseMaker is a homebrew software developed for sequence construction and formatting for 
integration with other softwares. As a python script, it can be opened in IDLE. When File>Load 
is selected, the file browser appears and asks for a csv file to load into the program, which then 
automatically generates a graph from the file (Figure 13). 
Using the text formatter, it was possible to efficiently change up to six substitutable values. Here, 
the text formatter was primed with text formatted for compatibility with ArduBridge automation. 
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The substitutable values defined were ❴1❵ the name of the category to file that sequence under ❴2❵ 
the name used to identify the sequence, which was different for every sequence ❴3❵ the 
description of the sequence, unnecessary if the sequence name and category already serve as 
sufficient identification ❴4❵ the amount of time (in seconds) the electrodes remain in the ON 
(actuated) state and ❴5❵ the period (in seconds) given to each actuation step of the sequence.  
To generate a sequence, the fields for ‘Electrode A’ and ‘Electrode B’ must be filled with the 
electrode numbers designating the start and end destination electrodes, or the electrodes at the 
two extremities relevant to the sequence being constructed. PaseMaker solves the shortest path 
between those electrodes and copies the formatted text string including that sequence to the 





        seqCategory = 'Dispensing'  
        seqName = 'Disp1to5'   
        seqDesc = 'DescriptionHere'  
        seqList = [[1], [1, 2], [2], [2, 3], [3], [3, 5], [5], 
[1, 5], [1, 5]]  
        seqOnTime=0.4  
        seqPeriod=0.6  
         
        self.seqAdd(seqCategory, seqName, seqDesc, seqList, 
seqPeriod, seqOnTime, ExtGpio, chipViewer) 
Figure 13) PaseMaker sequence construction example 
Example of sequence generation using PaseMaker. PaseMaker interface with text formatter (left) 
is primed with text formatted for the automation system’s ArduBridge software, and its 
substitutable values (top right) are primed with desired values. Here, the fields for Electrode A 
and B were assigned the values 1 and 5 to create a sequence which dispenses from electrode 1 to 
electrode 5. (Top) The resulting text is generated and copied to one’s clipboard in a split-second. 
(Bottom) 
 
After all sequences needed for the assay had been constructed this way, they were added 
into a python file in IDLE, referred to as the protocol file. This is a file necessary for ArduBridge 
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automation software to run. Until this step, every step only had to be done once. The next steps 
preceded every experiment. 
Once the protocol file contained all of the assay sequences, it was opened with LLGUI.exe. 
Opening LLGUI.exe makes the file browser pop up, so that one can find and select the protocol 
file. LLGUI reads the protocol and constructs a button interface with each buttons, representing a 
sequence, grouped under their category. Each category is initially collapsed. Clicking a category 
shows the buttons. (Figure 14) 
 
Figure 14) LLGUI.exe interface 
 
 
Each button represents a sequence. Every sequence is grouped under its category. Clicking a 
category will open or collapse that category. The number of times the sequence will be run is 
determined by the number entered into the #actuations text field (top right). The Arduino or its 
USB port can be closed or opened using the Open Port, Close Port, and Close Ardu buttons. 
 
Before beginning the experiment, unless this was already done and no other sketch had been 
uploaded since to the Arduino UNO, the compiled automation sketch was uploaded as a HEX 
file using an anonymously authored freeware bootloader program, XLoader.  
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The camera’s visualization software (uEye Cockpit) was opened to size and position the window 
before initializing the camera. (Figure 15) 
 
Figure 15) Desktop during a DMF experiment 
 
Screenshot of desktop appearance during an experiment with python-based GUI, python shell, 
and uEye camera software. 
 
Finally, ArduBridge could be opened in IDLE and run. However, there are differences 
that must be verified between users. First, the user’s choice of protocol file must be in the same 
folder as Ardubridge. Secondly, the user’s protocol filename and the comport specified for the 
Arduino has to be correct. These details are specified and changed by the user in the ArduBridge 




Figure 16) ArduBridge script by Guy Soffer 
Highlighted areas of the ArduBridge script which need to be changed between users 





Chapter 4. Assay Validation 
 
This chapter consists of work done in well plates to validate the MU-β-LacNAc assay. First, 
its ability to produce fluorescent methylumbelliferone upon hydrolysis is verified, after which 
inhibition of hydrolysis by fucosylation is tested. Enzyme concentration is optimized, followed by 
testing the inhibition of fucosyltransferase by GDP to produce an inhibition curve and measure 
IC50. 
 
4.1. Testing the Hydrolysis of MU-β-LacNAc 
 
 
 To confirm the functionality of the assay as well as optimize certain conditions, SpHex 
and BgaA were tested for their ability to hydrolyze MU-β-LacNAc. In a 384-well-plate, a 
solution with 10 µM MU-β-LacNAc, 50 mM Tris (pH 7.5), and 10 mM MgCl2 was incubated for 
10 minutes with either, neither or both of BgaA and SpHex at 0.05 mg/mL concentrations. It was 
demonstrated that SpHex and BgaA must both be included in the reaction to release a signal 




Figure 17) The hydrolysis of MU-β-LacNAc by BgaA and SpHex 
Bar graph reporting fluorescence of samples incubated either without, with one or with both 
of the Glycoside hydrolases β-gal from S. pneumoniae (BgaA) and N-acetylhexosaminidase 
from S. plicatus (SpHex). Glycoside hydrolases sequentially cleave synthetically 
methylumbelliferated disaccharide, MU-β-LacNAc, into its monosaccharide components, 
releasing fluorescent 4-methylumbelliferone (4-MU). Equivalent 4-MU concentrations for 
fluorescent signal was calculated by 4-MU standard curve. Experiments done in triplicate in a 









Optimal FucT concentration and hydrolysis reaction times were determined using the 
Clariostar® well-plate reader. With a negative control (0 nM FucT), seven concentrations of 
FucT were tested, spanning 1.248 nM (~0.07 mg/mL) to 0.089 nM. 770 uL each of 
‘glycosylation’ and ‘hydrolysis’ solution were prepared and primed into separate injectors. 11 uL 
of negative control and every FucT concentration was added to each well in advance, in 
triplicate. Clariostar® settings were created to automatically inject ‘glycosylation’ solution at the 
5 minute timepoint for each well. 10 minutes later for each well, hydrolysis solution was 
machine injected, after which fluorescence readings began; 10 timepoints were taken each 1 
minute apart and it was observed that fluorescence for each of the FucT concentrations reached a 
plateau in 5 minutes (Figure 18). Given these results, 5 minutes was selected as the minimum 
length of the assay’s hydrolysis step. A FucT concentration of 0.03 mg/mL, or 0.6 nM, was also 
chosen, given that the maximum fluorescent signal given by that concentration was sufficiently 
lower (20%) compared to the same reaction in the absence of FucT, providing a wide effective 





Figure 18) Determination of optimal FucT concentration and length of hydrolysis 
reaction 
Experiments done in triplicate a 384-well plate showing fluorescence intensity (y-axis) plotted 
against time (x-axis) for different FucT concentrations (legend – right side). When MU-β-
LacNAc was incubated in 50 mM Tris (pH 7.5) with MgCl2, GDP-Fuc and different 
concentrations of FucT, the resulting fluorescent signal was inversely related to the 
concentration of FucT. Fluorescence was measured once per minute for 10 minutes, showing 
that the time to completion of the hydrolysis is around 5 minutes. 
 
The precision of this test was examined by repeating the prior experiment with a single 
reading after 5 minutes, and only two FucT concentrations- 0.6 nM as a negative control (no 
hydrolysis; minimum fluorescent signal) and 0 nM as positive control (maximum hydrolysis; 
maximum fluorescent signal).(Figure 19) This assay yielded Z’ = 0.78 (n=8), which is excellent 




Figure 19) Fucosylation prevents hydrolysis and subsequent fluorescent signal 
Fluorescence bar graph evaluating the MU-β-LacNAc-based assay's potential for throughput 
application by comparing the signal with and without FucT and measuring its precision. 
Fluorescence reading performed after 5 minutes of hydrolysis reaction with MU-β-LacNAc 
and prior 10 minute incubation with 0.6 nM FucT or buffer. Equivalent 4-MU concentration 
calculated by fluorescence standard. Experiments done in a 384-well plate. Error bars 
represent standard error. *** : p < 0.01. (n=8) 
 
A baseline fluorescence was observed up to around the signal of  ~1 µM 4-MU, possibly 
due to the incomplete quenching effect of  MU-β-LacNAc on its 4-MU moiety. Though it has 
not been verified, it is possible that fucosylation further decreases the quenching effect, seeing as 
minimum fluorescence was higher in samples which included fucosylation compared to those 
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which did not. (Figures 17 and 19) In the future, this could be tested by measuring the 
fluorescence of MU-β-LacNAc over time while it is being fucosylated. 
 
In low-throughput assay runs, the Z-factor (Z’) value is a statistic that quantifies the 
response of an assay by comparing a set of positive and negative controls (Equation 7).193 It is 
often used to determine whether or not an assay is suited for potential high-throughput 
application.  
Equation 7) Estimated Z’ Factor 




In this formula, σ+ and σ- are the sample standard deviations of the positive and negative 
controls, and µ+ and µ- are the sample means. If Z’ < 0, then the positive and negative controls 
have too many similar readings for the assay to be useful. At 0 > Z’ < 0.5, then the assay is 
marginal. At 0.5 > Z’ < 1.0, the assay is excellent for high throughput. At Z’ = 1, the assay is 
ideal for high throughput. To obtain this value for the MU-β-LacNAc assay, the H. pylori α(1,3)-
fucosyltransferase—FucT— was used, for which GDP-fucose could act as the nucleotide sugar 
donor, with MgCl2 to supplement the metal ion.
194 It was shown that this fucosylation assay 
presents potential for high throughput application (Z’=0.78 in 384 well-plate). GDP was used as 
an inhibitor for FucT in proof-of-concept and IC50 values were collected, setting the groundwork 
for future screens of potential inhibitors for FucT and potentially many other 









Figure 20) Proof-of-concept: Inhibition curves using GDP 
Proof-of-concept fluorescence-reported inhibition curve obtained for GDP inhibition of FucT 
using the MU-β-LacNAc-based assay. Experiments done in a 384-well plate. Error bars 
represent standard error. 0 mM GDP was plotted as 10-10 mM. *Excluding the last point (40 mM 
GDP) results in the dashed sigmoid curve. (n=3) 
 
Previously, the nucleoside diphosphate GDP had been shown to be a weak (IC50 = 0.05 
mM) inhibitor for a recombinant human α(1,3)-fucosyltransferase via monitoring the 
fucosylation of di- and trisaccharides into tri- or tetrasaccharides.195 As such, GDP was used as a 
proof-of-concept inhibitor for the fucosylation of MU-β-LacNAc by FucT. A blank and a range 
of 10 GDP concentrations ranging from 0.08 mM to 40 mM during the reaction step were at first 
given 5 minutes of incubation with FucT mix (0.6 nM FucT), then the reaction was started with 
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the addition of  ‘glycosylation’ mix. 10 minutes later, ‘hydrolysis’ mix was added, 5 minutes 
after which fluorescence readings were taken, yielding GDP an IC50 = 0.25 ± 0.10 mM. (Figure 
20) It is worth noting that at the highest concentration of GDP (40 mM), fluorescence intensity 
had dropped by nearly half relative to the next highest concentration (a 20 mM GDP reaction). 
Excluding measurements taken at 40 mM GDP for the inhibition curve calculation would result 
in IC50 = 0.29 ± 0.07 mM, lowering calculated uncertainty but heightening calculated IC50. The 
bell shape of the inhibition curve was investigated after the inhibition assay had been otherwise 
optimized for DMF. All in all, these well-plate results were in accordance with GDP’s weak 
profile as an inhibitor as well as the assay’s model, in which the fucosylation of MU-β-LacNAc 
prevents its hydrolysis, and consequently, the fluorescent signal produced by the release of 4-




Chapter 5. DMF Platform Validation 
 
This chapter consists of the validation of the MU-β-LacNAc-based assay for DMF 
application, beginning with design considerations to improve droplet movement and dispensing, 
followed by the testing of surfactants toward the same ends, and then the validation of methods 
used to analyze data when performing the assay-on-chip. This concludes with the performance of 
the inhibition assay on DMF and the comparison of IC50 results obtained with those obtained in 
a well plate. 
 
5.1. Optimization of Fucosylation Inhibition Assay for Digital Microfluidics 
 
 
A chip was designed (Figure 11) which brings several novel features, from electrode shapes to 
serial dilutions on 3 or more orders of magnitude, to the area of digital microfluidic designs for 
enzymatic assays, allowing a variety of droplet operations on the device using our automation 
system (Figures 7 and 15). In the work reported here, we used a two-plate configuration (as 




5.1.1. Optimization of dispensing to prevent biofouling 
 
 In initial experiments, droplet movement failure was experienced with assay reagents 
containing proteins such as FucT, BgaA or SpHex, who could not dispense from their reservoirs. 
We hypothesize that this is most likely due to protein biofouling179, 180. Biofouling occurs when 
solutes adsorb to the chip surface, preventing any further droplet movement on the device. To 
minimize fouling at the dispensing step, five reservoirs were connected to additional inlet 
electrodes such that the solutions would rest on the reservoir for a minimal length of time. The 
ITO would be aligned with a third of the inlet electrode’s surface and by applying a driving 
potential to this inlet, the solution is loaded into the gap between the ITO and DMF surface. (See 
Figure 11 for loading steps.) These droplets can then be used immediately for the assay without 
having rested on-chip before they became needed. Dispensing was also optimized through the 
sequential design/fabrication/testing of DMF chips with different dispensing neck and electrode 
dimensions. 
5.1.2. Optimization of movement using oil and surfactants 
 
Merely optimizing dispensing was insufficient to prevent biofouling from all assay 
reagents. Aside from resting time spent by a solution on-chip, factors affecting droplet movement 
in DMF were studied: (1) the composition of reagents- from the properties of their solutes to the 
overall pH. 179, 180, 196 and (2) the shape and size of electrodes relative to droplet volumes.197, 198 
Many labs have addressed the former via the addition of PEO-containing triblock copolymers or 
‘Pluronics’ (BASF, Florham Park, NJ) to their solutions, some of which have been shown to 
increase the fouling threshold of protein concentrations for DMF by 1000-fold and to enable, for 
initially immovable cell culture media, from 100 to >300 steps of movement. 179, 180 An alternative 
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solution is to surround the droplets in an oil shell to minimize fouling and evaporation of the 
droplets. To these ends, the gap between the ITO and chip is commonly immersed with Silicone 
oil.199, 200 To determine the conditions in which the protein solutions used in the fucosylation assay 
would be capable of movement on the DMF device, an initial movement test was conducted with 
each of the proteins separately to discern which of them held the strongest biofouling capacity. 
BgaA was the least capable of movement. Speculatively, this could be due to its large size (~247 
kDa, which is  4.5 times the mass of SpHex and FucT). Larger molecules do not flow past each 
other as easily and are more polarizeable; both of these factors increase viscosity. 
As such, 0.05 mg/mL BgaA solutions were prepared with three different surfactant 
conditions: no surfactant, 0.05% Pluronics F-68, and 0.05% Pluronics F-68 while using pipette 
tips coated in silicone oil to dispense droplets (this process will simply be referred to as ‘with 
silicone oil’, although the resulting concentration is negligible). We also speculate that buffer 
conditions have an effect on droplet movement, and hence, we prepared solutions with three 
different buffer conditions: no buffer, 50 mM Tris, and 25 mM HEPES for a total of nine test 
solutions. Using the automation system, we manipulated the droplet between two target electrodes 
(crossing three electrodes in either direction to reach the other extremity) to implement the worst-
case scenario until either movement failed 3 times consecutively or until movement had been 
successful 24 times (3 more times than the maximum number of movements expected across any 




Figure 21) Movement of bulky protein solution using different buffers and surfactants 
Bar graph evaluating the effect of different surfactant conditions and silicone oil on the 
number of movements from one extremity to the other for a span of 4 electrodes for 0.05 mg/mL 
BgaA protein solutions on a DMF device before the movements would fail consistently (3 times in 
a row). Error bars represent standard error. (n=2)  
 
As shown in Figure 21, without the addition of surfactant, solutions were immobilized from 
the start. When 0.05% Pluronics F-68 was added to each of the three buffer conditions, droplet 
movement improved. Interestingly, without silicone oil, buffer composition also has an impact on 
droplet movement, in which fouling occurred after (on average) four movements for 50 mM Tris-
HCl and eight movements for 25 mM HEPES buffer. We are unsure what is the cause, but we 
speculate higher ionic strength prevents the ‘salting-in’ biofouling of molecules.196 The pH of 
buffers could also cause the degradation of the hydrophobic layer201, though this would have been 
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unlikely to be the cause given that pH 7.5 Tris-HCl was less acidic than the pH 7.0 HEPES buffer. 
The possibility remains, seeing as the pH of HEPES buffer is less sensitive to temperature than 
Tris buffer, only changing by 0.17 from 25°C to 37°C whereas the pH of 50 mM Tris changes by 
0.28. This could indicate greater suitability to DMF since the temperatures of electrodes can 
change upon actuation and could also be useful for future application when the assay is to be 
performed at biological temperature. The most notable improvement of droplet movement came 
with the application of both 0.05% Pluronics F-68 and silicone oil shells to BgaA solutions 
prepared with either buffer. Even though movement was stopped at 24 actuations, the droplets did 
not show any signs of slowing down. As a result of these tests, 0.05% F-68 with an oil shell and 




5.1.3. Testing DMF surfactant and oil impact on 4-MU fluorescence  
 
One of the major concerns in using an oil shell is the possible interactions it has with the 
aqueous droplet.  Hence, we tested the impact of surfactants and silicone oil on 4-MU fluorescence 
by preparing standards using two different DMF surfactants at 0.05%. For each of these 
concentrations, an identical set was prepared with 5% silicone oil. With the two surfactants tested, 
Ethylenediamine tetrakis(ethoxylate-block-propoxylate) tetrol (Tetronics 150R1) and Pluronics 
F68, oil had no effect on 4-MU fluorescence (p = 0.228, p = 0.143, N.S. > 0.05) (Figure 22, right). 
Increasing Tetronics 150R1 concentration heightened 4-MU fluorescence, but Pluronics F68 had 
the same impact on 4-MU fluorescence for each of the five concentrations tested (Figure 22, left). 
Seeing as oil and F68 concentration did not present a source of error for fluorescence readings and 
given the superior performance of droplet movement with this surfactant, Pluronics F68 with an 




Figure 22) 4-MU Fluorescence with different surfactant concentrations 
Standards prepared in a 384 well plate with different concentrations of Tetronics 150R1 and 






5.1.4. Optimizing electrode shape for droplet movement 
 
 
Figure 23) Skewed-wave electrodes compared to square electrodes 
View of shapes prepared in AutoCAD with a 1 mm scale for comparison. The first row shows 
four skewed-wave electrodes, the second row shows 7 square electrodes of equal area to skewed-
wave electrodes, and the third row shows 12 square electrodes of equal height to the skewed-
wave electrodes. All electrodes have 30 µm gaps between them. 
 
With the composition of assay solutions optimized for movement, another factor 
concerning droplet mobility was to be examined. Movement on a DMF device depends on the 
electric field between the top and bottom plates,165 which is affected by the shape of actuated 
electrodes. Typical electrode shapes are square or rectangular given the simplicity of drawing these 
shapes and the ease of their fabrication; however, droplets are known to become stranded, or 
‘static’ on an electrode when these volumes fail to overlap with adjacent electrodes, ceasing all 
movement.202 In response, some groups have designed interdigitated (ex.: “comb” or “zig-zagged” 
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edges) or otherwise original electrode shapes (ex.: alternating triangles).197, 203 Although this 
allows droplet movement for smaller volumes than simple rectangular electrodes, pointed shapes 
create regions with high electric fields > 108 V/cm which can cause dielectric breakdown.197, 203 
To alleviate this problem, intercalating electrodes were created with sinusoidal curves and 
minimum angles of ~90° where its edges join together, referred to as “skewed-wave” shaped. 
(Figure 23, top). Their dimensions ( 4.0 mm x 0.87 mm) were chosen so that upon actuation, the 
smallest resting droplet (~480 nL) would shrink vertically and stretch horizontally to reach 
adjacent electrodes in either direction. The length of these electrodes presented a second 
advantage: droplets could bridge long distances across the chip with a fewer number of electrodes 
and actuations. If square electrodes of the same area as a skewed-wave (1.5 mm x 1.5 mm) were 
used for the linear track, it would require up to 8 to bridge the length of 4 skewed-waves (thus 
increasing total electrode area by 75-100%), but the minimum volume of droplets would need to 
increase by ~27% to avoid becoming static. (Figure 23, middle) Square electrodes of the same 
height could be used to span the distance of 4 skewed-wave electrodes without increasing area or 
minimum volumes, but in this case, up to 13 electrodes would be required. (Figure 23, bottom) 
This is the first time that such an electrode shape is presented, and it can be used for experiments 
requiring reliable droplet movement with limited space on the substrate or pins/switches in the 
automation system. 
5.1.5. Optimization of dispensing by actuation sequence 
 
Initially, droplets were dispensed with a two-step process in which a liquid finger is pulled 
out from the reservoir by adjacent electrodes until the volume reaches a destination electrode, part 
of it still resting on the reservoir. Voltage was then applied to both the reservoir and the destination 
electrode to create a break in the liquid finger, splitting it into two volumes, the bulk of which 
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remained in the reservoir. Generally, droplets were successful in dispensing so long as the volume 
initially in the reservoir did not exceed 3.3 µL, at which point too much of the volume remained 
in the reservoir and on the neck to cause its separation at the splitting step, or drop below 2 µL, at 
which point the liquid finger was no longer in contact with the reservoir on the crucial splitting 
step. Reservoir volume generally dipped below the lower threshold after 2 or 3 dispensed droplets. 
However, this dispensing limit was circumvented by replacing the two-step dispensing process 
with a ‘Low-volume dispensing’ sequence that would gradually separate the volume from its 
droplet by continuously actuating the destination electrode while also actuating the electrodes 
leading back to the reservoir, inching back toward it two electrodes at a time until splitting 
occurred. (Figure 10.) This actuation sequence ensured that we were capable of dispensing 3-4 








Figure 24) Pixel count being used to calculate a dilution factor 
Magnetic lasso tool was used in Adobe Photoshop CS5 and Creative Suite with anti-aliasing 
(takes into account the blurriness of edges while counting pixels), 3 px width (influences 
sensitivity), 10% contrast (influences sensitivity), and 80 frequency (how often it searches for the 
next point while tracing the edge). 
 
Given all of the factors that could impact droplet size (See 1.3.4) and hence the validity of 
our analyses of the data obtained downstream, and one of the benefits of digital microfluidics- its 
amenability to automation, we worked towards the goal of creating an automated analysis tool that 
can directly calculate the concentrations in our samples instead of using inline detectors or external 
plate readers. We have created an image analysis method, referred to here as Pixel Count (PC) 
which measures the volumes on the device and uses a standard dilution equation (C1V1=C2V2) to 
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calculate the final concentration of the sample. (Figure 24) The workflow of this consists of 
recording images of the device and porting these to Adobe Photoshop where an edge-finding 
algorithm was used to determine droplet areas from which volume can be extrapolated (similar to 
work by Vo et al.145). In the future, Pixel Count should be used with open source edge-finding 
algorithms integrated into DMF programs which could record and respond to these concentrations 
from automated image analyses. 
 
Figure 25) Accuracy and Precision of Pixel Count as a method of volume measurement 
Bar graph plotting volumes measured by either precision balance or pixel count (y axis) grouped 
by the volumes pipetted by micropipette (x axis). Error bars represent standard error. Different 
small volumes (0.5, 1, 1.5 and 2 µL represented on the x axis) were pipetted onto a DMF device 
from a 0.2-2 µL micropipette and volume measured by weight using a precision balance (n=6) 




Using PC, initial volume (before dilution) and final volume (after dilution) could be 
determined. To validate PC, we first tested it against the volumes given by micropipette and by 
precision balance. (Figure 25) A range of volumes (0.5-2 µL) were pipetted onto the device 
mounted on a precision balance, for which a change of weight reported volume. The same range 
of volumes was pipetted onto a device which was rapidly covered by an ITO then measured by 
PC. As shown in Figure 25, the volumes calculated by PC are a closer match to those given by the 
micropipette and are exhibit more precision than those reported by the precision balance.  
 
To calculate droplet volume by pixel count, the known dimensions of an element of the 
chip image could be used to obtain the equivalent area of the droplet in mm2, which can then be 
multiplied by the measured gap height of the chip to result in a mm3 measurement of the droplet. 
(Table 2 and 3) The volume of these aqueous solutions is obtained given that 1 mm3 of volume 
should approximate 1 µL. (Equation 8) 
Equation 8) Calculation of droplet volume by pixel count 
𝑉𝑑𝑟𝑜𝑝𝑙𝑒𝑡 = 𝑑𝑟𝑜𝑝𝑙𝑒𝑡𝑝𝑖𝑥𝑒𝑙𝑠 ×  
𝑘𝑛𝑜𝑤𝑛𝑚𝑚2
𝑘𝑛𝑜𝑤𝑛𝑝𝑖𝑥𝑒𝑙𝑠
 × 𝑔𝑎𝑝𝑚𝑚 
Where Vdroplet is the volume of the droplet in µL, dropletpixels is the area of the droplet 
measured in pixels, knownmm
2 is the known area of a measurable feature in the chip image in 
mm2, knownpixels is that same feature’s area measured in pixels, and gapmm is the height of the 




Table 2) Calculating the mm2 per pixel factor using the known size of a visual element of 
the chip design  
 
 




For each initial solution, the initial concentration was known- and with pixel count, initial 
volume and final volume were also known. As such, the final concentrations could be calculated 




5.1.7. Testing homogeneity of solutions mixed on DMF device 
       
 
Figure 26) Testing the homogeneity of the fluorescence of dispensed droplets from a 
volume mixed on-device 
Droplet of 50 µM 4-MU solution (top), from which one droplet was dispensed and mixed with 
a droplet of buffer. 5 droplets were then dispensed from this dilution (middle) and scanned, 
then visualized with a fluorescence heat-map.  
 
The homogeneity of mixing solutions on device was tested by dispensing a droplet of 4-
MU at high and low concentrations into 2.7 µL buffer. These volumes were then mixed and from 
each, 5 droplets were dispensed. The fluorescence of these resulting droplets was measured, 
showing a high degree of homogeneity among the concentrations of droplets dispensed from a 




Figure 27) Dispensed droplets fluoresce homogenously from a volume mixed on-device 
Fluorescence bar graph comparing the fluorescence of droplets diluted from different initial 4-
MU concentrations to determine homogeneity of mixing. Corresponding 4-MU was calculated by 
fluorescence standard obtained on device. Droplets were dispensed from [4-MU]ini = 50 mM 
(High), 2.5 mM (Low; Left)  (n=5) 
85 
 
5.1.8. Testing calculation of 4-MU concentration: Pixel Count validation 
 
Figure 28) Concentration of diluted 4-MU droplets calculated by fluorescence VS. pixel 
count. 
Comparing, with diluted droplets from high and low initial 4-MU concentrations in 25 mM 
HEPES buffer, the concentration of 4-MU calculated by fluorescence standard VS. that which is 
calculated by pixel count. [4-MU] calculated by fluorescence were done through 4-MU 
standards on device. [4-MU] calculated by pixel count were done by dividing the initial 
calculated [4-MU] (by fluorescence) by the dilution factor calculated by pixel count. (n=5)  
 
Finally, we quantitatively verified PC-based calculation of concentrations. Both the 
parent solution droplets and each of their 5 diluted progeny droplets had their 4-MU 
concentrations calculated using a standard linear regression from 4-MU standards pipetted and 
measured on-device. From the same initial concentration of 4-MU, PC was used calculate the 
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concentrations of the diluted droplets. Both fluorescence-based and PC-based methods showed 
excellent agreement in their values (Figure 28). Hence, the PC method for calculating 
concentrations seems to be analogous to the well plate reader as long as C1 is known, without 





5.2. Inhibition Assay on DMF Device 
 
5.2.1. Serial dilutions on chip 
 
Inhibition assays generally span at least 3 degrees of magnitude. However, serial dilutions 
insofar have been limited on DMF devices. Sequential 2-fold dilution factors, wherein a droplet of 
buffer and of solution are mixed together then split apart into two equal volumes, have been used 
to generate up to 8-fold dilutions at which point errors in dilution factor reached ~25% in only 
three dilution steps.181, 204, 205 Most of this error can be accounted for by variations in dispensed 
and split volumes.181 To span a 1000-fold dilution factor, 10 such 2-fold dilution steps would have 
been needed. To avoid the considerable compounding error this would entail, a different dilution 
strategy was necessary. Five reservoirs were primed with 2.7 µL buffer. A ~0.5 µL droplet of GDP 
solution serving as inhibitor for proof-of-concept was dispensed and mixed with the contents of 
the first reservoir. (Figure 11.) A droplet was then dispensed from this reservoir and mixed with 
the buffer in the second reservoir, and so on until 5 cycles of approximately 5-fold serial dilution 
had been achieved. Given the initial GDP stock and negative control (only buffer), by the end of 
these steps, there were 7 samples spanning a dilution factor surpassing 5000-fold on-device, for 
which each concentration could be calculated using the pixel count method with an estimated 
±2.4% standard error for each dilution step accounted for by the pixel count method (obtained by 
measuring different reservoirs of known equal area across the same snapshots of a chip (n=15) and 
compounding the average ±1.7% standard error of the measurements for initial and final volumes). 
As such, the error of pixel-count calculated GDP concentration should span from ±2.4% at the first 
dilution up to a compounded ±12% after 5 steps of serial dilution (>5000-fold), which is a marked 
improvement over ±25% at the 8-fold dilution mark. After two droplets were dispensed from each 
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dilution of GDP and the remaining waste volumes removed, the inhibition assay could take place 
(Figure 11.) Despite using pixel count to lessen the compounding error in serial dilution steps for 
the inhibitor concentration, other sources of error for the IC50 value reported on DMF device 
remain present. Notably, the variation in the reaction concentrations of the assay components can 
be expected to be slightly different between every sample due to the variability in dispensed 
volumes. While pixel count could technically report the concentrations for other important assay 
components (the glycan MU-β-LacNAc, the sugar-donor GDP-fucose, the fucosyltransferase 
FucT…) this information could not be used to reduce the error that this variation in other 
concentrations has introduced to the fucosyltransferase inhibition assay. 
 
5.2.2. Inhibition of a fucosyltransferase on chip  
 
To evaluate the potential for testing inhibitors for fucosylation assays on digital 
microfluidic devices, we created a microfluidic system that generates a serial dilution of the 
inhibitor, spanning at least four orders of magnitude.  After optimizing conditions for this assay to 
be held on a digital microfluidic device, GDP was tested as a proof-of-concept inhibitor for FucT. 
Figure 20 shows the evaluation of the dose-responsive inhibitory activity of GDP, reported by 
fluorescence, together with well plate results for comparison.  
On the DMF device, in addition to the blank (0 mM GDP), six GDP concentrations were 
generated via a series of ~5.5-fold dilutions, for which each concentration was calculated using 
our PC method. The assay was then performed on-device with 0.03 mg/mL FucT. (Figure 11, 
Online video: https://www.youtube.com/watch?v=Ehot1basdzM ) Compiling the results from 
three runs of the assay, the IC50 value initially obtained for GDP inhibition of FucT was 0.180 
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mM ± 0.199. Similarly, we implemented the same assay in a well plate and achieved an IC50 





Figure 29) Inhibition curves using GDP 
FucT inhibition assays with GDP done in a 384-well plate (A, C) or on DMF device (B, D) 
before (A, B) and after (C, D) glycine dilution. Error bars represent standard error. IC50s were 
drawn and fitted to the formula y=b+((a-b)/(1+(x/c)d)) using a least squares routine by 
GNUPLOT-powered software available online at: (http://www.ic50.tk). Sigmoid curves and 
corresponding 0 mM GDP was plotted as 10-10 mM. Before glycine dilution, 40 mM GDP points 
were marked with an asterisk (*) and excluded as outliers. (n=3) 
 
However, as previously seen at the proof-of-concept stage, the fluorescence intensity 
recorded for samples at the highest GDP concentration (~40 mM) was dramatically lowered. 
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Typically, this reversal of response to inhibitor concentration following what appears to be peak 
inhibition is attributed to bell-shaped dose-response curves, in which multiple binding sites, 
multiple targets, or the aggregation of drug into colloids at certain concentrations negatively 
impacts inhibition after inhibitor concentration crosses above a certain threshold.206-208 Given that 
4-MU is prone to shifts in its emissions peak in response to differences in ionic conditions, pH, 
and % water content,209 it was hypothesized that the bell-shaped dose-response curve was not due 
to differences in inhibition, but rather, that it could be due to an as-of-yet unidentified quenching 
effect of our concentrated neutral-pH GDP solution upon 4-MU. ( For structurally related 
compounds to 4-MU, halide ions, aromatic amines, acetone and flavonoids have all been reported 
as quenchers.210 ) To test our speculation, we equilibrated assay solutions by subjecting them to a 
5-fold dilution in pH 10.4 1M glycine. As shown in Figure 29, this immediately restored the curve 
to a sigmoidal fit when performed, both on the well plate (R2 = 0.718, p > 0.05; N.S. to R2 = 0.989, 





Figure 30) IC50 comparison before and after glycine dilution on both well plate and DMF 
device 
Bar graph comparing the IC50 reported by DMF device and that reported by the same assay 
solutions (with oil and surfactant) in a 384-well plate. Data points taken at 40 mM GDP were 
excluded in the IC50 calculation prior to glycine dilution on well plate only. (n=3) 
 
Due to the heightened fluorescence it displayed at an elevated pH, it was not necessary to 
adjust gain and settings on the well-plate reader: similar standard linear regressions were obtained 
for 4-MU with these settings both prior and after the glycine step on both well-plate and DMF 
device (Figure 31). The values reported by the inhibition assay after glycine dilution were 
relatively consistent with each other at 0.114 mM ± 0.086 on well plates and 0.093 mM ± 0.037 





Figure 31) 4-MU standards subjected to 5-fold dilution in pH 10.4 1M Glycine 
Standard linear regressions of 4-MU fluorescence on a DMF device before and after a 5-fold 
dilution in pH 10.4 1M glycine. Error bars represent standard error. All standards prepared 
with 0.05% pluronics and pipette tips coated with silicone oil. 
 
Even prior to glycine dilution, reaction solutions in DMF conditions further altered the 
fluorescence intensity observed to report equivalent 4-MU concentrations which were much higher 
than the theoretical maximum given by the 10 µM MU-β-LacNAc present in solution , despite that 
the 4-MU standards had been prepared with the same buffer and surfactant conditions. While 
heightened fluorescence could in part be explained by the reflectivity of metallized electrode 
surfaces in DMF, the well plate results demonstrate highly similar behavior, indicating that some 
property of the reaction components other than buffer and surfactant alone might enhance 4-MU 
fluorescence. Due to the nature of concentration dose-response curves, this discrepancy between 
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the fluorescence intensity reported by 4-MU standards in contrast with the product of hydrolyzed 
MU-β-LacNAc in reaction conditions had no impact on their ability to report IC50 values.  
Additionally, the early proof-of-concept inhibition curve obtained in non-DMF optimized 
conditions (no surfactant, oil, or HEPES buffer) had neared its lowest inhibition state with only a 
500-fold dilution, whereas dilutions of GDP tested in DMF conditions in the well plate were of 7 
concentrations spanning from 1 to 1845-fold and still hadn’t attained their lower plateau. This 
would suggest heightened inhibitory effect on FucT (higher fluorescence) even at lower 
concentrations of GDP, possibly due to the inhibitory effect oil surfactants can have on enzymes.211  
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Chapter 6. Concluding Remarks 
 
In conclusion, the labelled synthetic disaccharide MU-β-LacNAc has shown itself to be a 
reliable target substrate and a useful probe for fucosylation and fucosylation inhibition by FucT, 
with potential for high throughput application (Z’ = 0.78 in 384 well plate,) although such an 
application is not found in this work. Though the DMF system used is outperformed by robotics 
when it comes to multiplexing, it has served to develop methods 145, 148 and other types of 
enzymatic assays on digital microfluidics devices 212 at an affordable fraction of the cost 
associated to robotic fluid-handling systems, while economizing on substrate-consumption costs.  
In this work, DMF permitted the same reactions to be held at an 87.5% reduction of the minimal 
volume used in a 384-well plate. It was used to generate serial dilutions of GDP for the inhibition 
of H. pylori α-1,3-fucosyltransferase, FucT, using MU-β-LacNAc as a target substrate. Dose-
response curves were obtained. We also show results related to optimizing the device conditions 
for performing the assay, such as electrode design and the testing of droplet dispensing and 
movement with surfactants and an oil shell. Serial dilutions spanning 4 degrees of magnitude 
were carried out on a DMF device for the first time, with inhibitor concentrations calculated 
through image analysis so as to circumvent part of the error typically associated to serial 
dilutions on this platform. Comparable performance was shown between 384-well plate and 
DMF device, with similar IC50 values for GDP (0.114 mM ± 0.086 and 0.093 mM ± 0.037, 
respectively).  
We report the alteration of a bell-shaped inhibition curve for GDP into a sigmoidal shape 
when assay samples are subjected to a 5-fold glycine dilution on well-plate and on DMF device, 
demonstrating that the dip in fluorescence at high GDP concentration was not due to a change in 
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the reaction, but rather, to a change in the fluorescence of 4-MU. In future work, we hope to 
discern the assay component(s) responsible for enhanced 4-MU fluorescence in assay conditions; 
for now, we know that DMF surfactants and HEPES buffer are not solely responsible. 
We also report a skewed-wave electrode design allowing droplets in a large range of sizes to 
move quickly across longer spans per electrode used. Additionally, a GUI was built as a 
controller for a Python 2.7-based framework. PaseMaker (Path Sequence Maker), a Python 2.7-
based universal path-solver, was created to generate electrode actuation sequences for 
dispensing, mixing, moving, splitting, low-volume dispensing, and circular mixing on any digital 
microfluidics chip design. It has been made available as an open-source software. Its true 
potential lies in its integration with DMF control programs which include a visual representation 
of one’s electrode layout, allowing it to generate the actuation sequence after a user visually 
designates electrodes. One such DMF control program, Nelumbo, which integrates PaseMaker is 
already in the works by Philippe Vo. Due to its ease of integration with other softwares and 
universal applicability to DMF designs, I envision that PaseMaker could some day help in 
speeding up the pace of DMF work in many labs. In future work done on this program, perhaps it 
could be developed into a python module or have a visual electrode layout builder incorporated 
in its GUI. PaseMaker has also been structured in a manner that it should be possible to instruct 
it to route droplets through alternate paths when necessary to avoid fouled electrodes, or to 
automatically solve the path through the least used electrodes, but this functionality has not yet 
been implemented. 
The ease of integration of DMF automation with computer electronic hardware and software 
components, combined with the individual manipulation of on-device volumes, grants it 
unparalleled versatility when it comes to computerizing and automating laboratory protocols- in 
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the future, image-processing algorithms using the pixel count concept tested in this work could be 
used for DMF operation to automatically respond to visually cued variables to reduce experimental 
error by maintaining reservoir volumes in specific ranges for dispensing reproducible droplet 
volumes, precisely calculating concentrations generated on-chip instead of relying on estimates, 
and using alternate dispensing options (such as the low-volume dispensing sequence described in 
this work). 
Finally, toward the continued facilitation of drug discovery for inhibitors of 
fucosyltransferases, as well as the development of diagnostic and research tools for glycome-
modifying diseases, future work could continue to expand the repertoire of tools available to test 
for glycosylation and its inhibition. For example, MU-β-LacNAc could also be used as an acceptor 
substrate in other glycosylation assays. One could also synthesize the sialylated form of MU-β-
LacNAc, a  methylumbelliferated Sialyl-LacNAc, to assay for the inhibition of Sialyl-LewisX 
formation. Like the LewisX formed by the fucosylation of MU-β-LacNAc, screening for inhibitors 
of glycosyltransferases involved in Sialyl-LewisX formation could lead to the discovery of drugs 
to combat metastasis, drug-resistance and proliferation in cancers, host colonization by pathogens, 
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Introduction to DMF Automation Systems 
 
In a given DMF experiment, there are many types of operations to be performed on a 
device. The simplest form of DMF device operation comes from direct application of a potential 
to the desired electrodes by touching the positive wire of a circuit to a contact pad which is 
connected to the electrode, while touching the negative wire of a circuit to the ground. This 
would not only considerably slow the pace of an experiment and require manual dexterity, it 
would also render impossible certain operations which require fast sequential actuations of 
different electrodes and cut out the possibility for automation entirely. In order to facilitate the 
efficient operation of DMF chips, many labs develop automation systems and softwares 
independently of one-another. This does not take advantage of the potential of DMF as 
something that could be shared by any lab and downloaded by others in the manner of plug-and-
play, both with regards to the design of devices and the experiments that are run by them. Cross-
platform, open-source software that is user-friendly enough and compatible enough with other 
modules could help to reach that goal. 
LLGUI 
 
The initial automation system available was run through MATLAB (MathWorks) and 
coded in C++. Its advantage was its GUI (user interface) which allowed one to visually select 
electrodes to actuate and visually construct sequences from an array-based representation of the 
electrode layout. However, it was prone to glitching, and sequences needed to be loaded 
individually by inputting their file names. This would make any experiment involving the 
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responsive use of many sequences very arduous to run. Additionally, the MATLAB code was too 
difficult to decipher for non-coding labmates, making it impossible for them to debug, remix or 
expand upon what was already there to add additional functionalities. As such, a second 
automation system called ArduBridge was developed by Guy Soffer, which runs on the cross-
platform coding language, Python 2.7. Comparatively more easy to teach and learn than 
MATLAB, labmates could now easily add to and expand upon it. 
ArduBridge was run by inputting commands through the Python shell (IDLE). This 
would require entering a string of code into the python shell every time one wishes to actuate an 
electrode sequence during an experiment. To prevent slowing down device operation by 
repeatedly typing, and having to remember all of the sequence names, I created a GUI ( LLGUI) 
to be used as an interface for ArduBridge, with help from Guy Soffer. To make LLGUI possible, 
ArduBridge’s protocol file was also modified to include sequence categories and descriptions.  
Typically, LLGUI read the user’s ArduBridge protocol file and created a window with a 
button for each droplet operation sequence. (Figure 14) These sequence buttons were grouped 
under their similar droplet operation categories (dispensing, movement, mixing, and stashing or 
unstashing from reservoirs) to facilitate organization and visual interpretation. A text input box 
allowed the user to specify the number of repeats required for the sequence. Hovering over a 
button displayed the tooltip (sequence description) and clicking the button copied the command 
string to one’s clipboard (this was achieved by using the python module, ‘pyperclip’). This could 
then be pasted in the shell, from which one could begin sequence actuation. LLGUI also 
included a button which would copy the ArduBridge command for closing the Arduino. 
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Since that time, a new version of LLGUI came out with a few more additions by myself 
(better space allocation) and Guy Soffer (buttons for opening or reopening the connection to the 
Arduino through the USB port, and clicking the buttons now immediately actuates the sequence).  
PaseMaker (Path Sequence Maker) 
 
Writing dozens of actuation sequences with a hundred numbered electrodes on a DMF 
device can be costly with regards to time and human error. A program called Pasemaker.py was 
created to automate construction of electrode sequences universally (for any and all DMF designs), 
with thought to compatibility with other softwares and future functionality.  
When PaseMaker is used alone, users provide a .csv file listing each electrode of a DMF 
device as its reference pin number on a separate row, and for each electrode, the electrodes adjacent 
to it are listed in any number of columns on that same row. From this information, Pasemaker 
constructs non-visual graphs which map out the DMF chips as networks in which every electrode 
is a node and every connection between electrodes is of a certain distance (the distance is 
automatically assigned as 1). Pasemaker’s windowed interface allows users to load their .csv from 
a file browser/picker, after which it allows them to view, select and copy to the clipboard the raw 
numeric graph produced by Pasemaker. In a text input box on the interface, the user could choose 
to provide a customizable string in which they could specify where the sequence would be inserted 
once it had been created. In two other provided spaces, the user could enter the pin number of the 
start and end point electrodes, after which they could select what kind of sequence they wished to 
construct between those for Moving, Dispensing, Low-Volume Dispensing, Mixing in a line, 
Mixing in a circle, or Splitting of volumes between the two user-specified electrodes. (Table 4) 
Pasemaker would then use Dijkstra’s Algorithm to solve for the shortest path and format it into 














from A to B)  
Solves shortest path from A to B and constructs the 
electrode sequence from A to B 
Dispense 
(Dispenses from 
A to B)  
Solves shortest path from A to B and constructs the 
electrode sequence from A to B, then appends the 
simultaneous actuation of A and B 
Disp-LV (Useful 
to dispense from 
A to B even 
when volume in 
A is low) 
 
Solves shortest path from A to B and constructs the 
electrode sequence from A to B, then, while keeping 
electrode B actuated at every step, appends the actuation 
of electrodes in reverse order (from B to A), ending with 
the simultaneous actuation of A and B 
Mix-I (Mixing 
in a straight line 
A⇄B)  
Solves shortest path from A to B and constructs the 
electrode sequence from A to B, then appends the same 
sequence but with reversed order. 
Split (Splits a 
central volume 
to A and B)  
Solves shortest path from A to B. Checks the number of 
electrodes: if odd, there is a single central electrode. If 
even, there are two central electrodes. Constructs the 
electrode sequence to actuate the central electrode(s) then 
simultaneously actuate a path from the central 
electrode(s) to A and to B. 
Mix-O (Mixing 
in a circle 
encompassing A 
and B)  
Computes whether or not A and B are mutually connected 
to two other, separate electrodes. If so, then the path from 
A to B across one of these mutual adjacents is appended 
to the path from B to A across the other of the mutual 
adjacents. The sequence is constructed, then appended to 
















Move 1 to 5 ⦗⦗1], ⦗1, 2], ⦗2], ⦗2, 3], ⦗3], ⦗3, 5], ⦗5]] 
Dispense 1 to 5 ⦗⦗1], ⦗1, 2], ⦗2], ⦗2, 3], ⦗3], ⦗3, 5], ⦗5], ⦗1, 5], ⦗1, 5]] 
Disp-LV 1 to 5 ⦗⦗1], ⦗1, 2], ⦗2], ⦗2, 3], ⦗3], ⦗3, 5], ⦗5], ⦗5, 2, 3], ⦗1, 2, 5]] 
Mix-I 4 to 6 ⦗⦗4], ⦗4, 5], ⦗5], ⦗5, 6], ⦗6], ⦗6], ⦗5, 6], ⦗5], ⦗4, 5], ⦗4]] 
Split 4 to 6 ⦗⦗5], ⦗4, 5, 6], ⦗4, 6]] 
Split 4 to 7 ⦗⦗5, 6], ⦗4, 5, 6, 7], ⦗4, 7]] 
Mix-O 7 to 10 
⦗⦗7], ⦗7, 8], ⦗8], ⦗8, 10], ⦗10], ⦗10, 9], ⦗9], ⦗9, 7], ⦗7], ⦗9, 
7], ⦗9], ⦗10, 9], ⦗10], ⦗8, 10], ⦗8], ⦗7, 8], ⦗7]] 
 
 ‘Bussing’ is the term given to a situation where multiple separate electrodes are controlled 
by the same switch, and as such, always actuate at the same time. Some DMF designs employ this 
to save space or to have more electrodes than the number of available control switches. To be fool-
proof, Pasemaker automatically detects electrode bussing and assigns them different IDs in the 
graph so as to distinguish between spatially separate electrodes throughout its path-solving and 
sequence construction operations even if they shared the same pin number. If either or both of the 
electrodes specified for path solving were bussed, a window would pop up asking the user to select 
which of the displayed bussed electrodes to use for path solving and sequence making.  
 
